Index,Date,Name,Tweet
1,Wed Apr 29 01:12:14 +0000 2020,Yelena Y. Janjigian MD,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
2,Wed Apr 29 01:12:21 +0000 2020,Alan Meng,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
3,Wed Apr 29 01:12:28 +0000 2020,Bruno Larvol,"I am not sure what to make of the multiple presentations at #AACR20 that ask for slides to not be posted.  I am looking out for it and not posting images of the slides, but its a bit odd in the setting of a meeting that is completely online with free universal access."
4,Wed Apr 29 01:12:28 +0000 2020,Kimberly Gwaltney,Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW
5,Wed Apr 29 01:12:37 +0000 2020,6ustv,".@VirusesImmunity &amp; Anna Marie Pyle: A stem loop RNA that stimulates RIG-I activation delays tumor growth, extends survival, and prevents tumor recurrence. JEMâ€™s cancer collection for #AACR20 (https://t.co/G1mQsSpTaZ) has summaries of articles in this PDF: https://t.co/Hec3sDfz71 https://t.co/opwHDK5OAQ"
6,Wed Apr 29 01:13:59 +0000 2020,"Sanaz Soltani, MD",Pre existing ESR1 mutations in early stage primary breast cancer predict failure of endocrine therapy and poor OS. This is important and should guide how we think about ER+ breast cancer. #aacr20 https://t.co/DC3ROEJt4l
7,Wed Apr 29 01:14:38 +0000 2020,Amy A. Baran,Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG
8,Wed Apr 29 01:15:22 +0000 2020,Alan Meng,TMB is an #immunotherapy biomarker with tumor type agnostic potential. The use of #TMB has been hindered by the fact that commercial labs measure TMB differently. Pleased to see the hard work of the TMB harmonization project presented today at #AACR20 and published in #JITC. https://t.co/w2AUTikbaM
9,Wed Apr 29 01:15:46 +0000 2020,NCI Treatment,"Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3"
10,Wed Apr 29 01:18:00 +0000 2020,gilberto lopes,"Dear Colleagues,
Thank you for a great couple of days of science, all of us at @OncoAlert ğŸš¨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2âƒ£.
Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC"
11,Wed Apr 29 01:18:46 +0000 2020,Pavel Reinoso,"#COVID19 #AACR20 #LCSM
TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.
198 pts evaluated with 34.6% of death rate.
Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi"
12,Wed Apr 29 01:19:00 +0000 2020,MD Anderson Cancer Center,"â€œOur preclinical data suggest that IPN60090 may be effective in underserved groups of patients who need better treatment options,â€ says our Dr. Jeffrey Kovacs: https://t.co/nAcAdjEdXQ #AACR20 #CancerMoonshot #endcancer"
13,Wed Apr 29 01:19:37 +0000 2020,Andres F. Cardona,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
14,Wed Apr 29 01:19:42 +0000 2020,Becky Bunn,Conclusion for TERAVOLT registry presentation on #AACR20 https://t.co/hR3R47wVNK
15,Wed Apr 29 01:20:38 +0000 2020,Pedro Pablo Prada ğŸ‡¨ğŸ‡º,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
16,Wed Apr 29 01:23:00 +0000 2020,Juan Salvador,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
17,Wed Apr 29 01:23:09 +0000 2020,"Lecia Sequist, MD, MPH",Important summary of key #COVID19nCancer data from #AACR2020. Thanks @CharuAggarwalMD
18,Wed Apr 29 01:24:08 +0000 2020,Alan Meng,.@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg
19,Wed Apr 29 01:24:42 +0000 2020,FlorDePitaya,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
20,Wed Apr 29 01:24:46 +0000 2020,UChicago CGH,"Missed #COVID19nCancer plenary in #AACR20 @AACR?
Hereâ€™s a thread to catch up on all the fascinating global research presented by:
@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology"
21,Wed Apr 29 01:25:11 +0000 2020,"Antonio Giordano, MD PhD","Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
22,Wed Apr 29 01:25:49 +0000 2020,Alan Meng,Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht
23,Wed Apr 29 01:26:35 +0000 2020,Alan Meng,Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM
24,Wed Apr 29 01:27:46 +0000 2020,Alan Meng,"Nice presentation by Dr Sridhar (AstraZeneca) showing that tertiary lymphoid structures (assessed by gene signatures expression) are associated with response to anti-PD-L1 durvalumab in #NSCLC and UC, extending our results from soft tissue sarcoma and melanoma. #AACR20 https://t.co/ZWZ30ATRIF"
25,Wed Apr 29 01:27:58 +0000 2020,Pedro Hdez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
26,Wed Apr 29 01:28:35 +0000 2020,"Thierry Alcindor, MD, MSc",It would be interesting to know whether the same gene expression pattern is seen across different tumor types.
27,Wed Apr 29 01:29:53 +0000 2020,Just Deb,"Okay, I was not going to announce this till we actually had a cure but here goes: @Aiims1742  @VivekSubbiah and @UroDocAsh have formed a secret society in Harris County. 

Come join us at happy hour April 1, 2021 to learn what we have been up to @WSJ #AACR20"
28,Wed Apr 29 01:30:50 +0000 2020,Daryseg,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
29,Wed Apr 29 01:31:30 +0000 2020,David PÃ©rez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
30,Wed Apr 29 01:31:37 +0000 2020,Keith T Schmidt,Great presentation by Dr. Padmanee Sharma of @MDAndersonNews @AACR #AACR20 on why PD-1 and PD-L1 inhibitors performed poorly in #mCRPC to date and what the next steps should be https://t.co/0vT59YkLKy
31,Wed Apr 29 01:32:10 +0000 2020,Marino20CğŸ‡¨ğŸ‡º,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
32,Wed Apr 29 01:33:18 +0000 2020,ã¯ã‚“ãªã‚Š #Stay home!,"Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
33,Wed Apr 29 01:35:03 +0000 2020,Alan Meng,"CONGRESS | #AACR20 | Yuan-kai Shi presents results from a phase II trial of geptanolimab (GB226), an anti PD-1 humanized, monoclonal antibody, in patients with R/R PTCL #lymsm https://t.co/WMsnNysH0Z"
34,Wed Apr 29 01:35:23 +0000 2020,"Walt Whitman, NP","You can never be too respectful, so always err on the side of showing more, not less, respect. #pallonc #oncology #hapc #nursing"
35,Wed Apr 29 01:37:16 +0000 2020,Alan Meng,"Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9"
36,Wed Apr 29 01:41:52 +0000 2020,Jiayi Huang,"Catching some of the @AACR virtual meeting today, super cool stuff. Makes me *very* excited for future virtual conferences! #AACR20 

PS Fantastic discussion of social determinants of health during the #COVID19 session. Dont miss!

PPS Virtual @roecsg in &lt;3 weeks what up! ğŸ‰ğŸ¥³ğŸ˜€"
37,Wed Apr 29 01:44:02 +0000 2020,ç€¬æˆ¸å†…æµ·ã«è‡¨ã‚€ã€€ä¹³è…ºå¤–ç§‘åŒ»,"ã€#AACR20 COVID-19ã¨ãŒã‚“åŒ»ç™‚ã®ãƒ—ãƒ¬ãƒŠãƒªãƒ¼ã®æ¦‚è¦ã¨æ„Ÿæƒ³, part 2ã€‘
COVID-19ï¼†ãŒã‚“ã«ãªã£ãŸã¨ãã®äºˆå¾Œä¸è‰¯ã®ãƒªã‚¹ã‚¯
- ç™ŒãŒè‚ºã«è»¢ç§»ã—ã¦ã„ã‚‹ã‹è‚ºãŒã‚“ã§ã‚ã‚‹
- ARDS
- å¥½ä¸­çƒæ¸›å°‘ç—‡
- ï¼‘ï¼”æ—¥ä»¥å†…åŒ–å­¦ç™‚æ³•"
38,Wed Apr 29 01:44:16 +0000 2020,Katie Kurnit,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
39,Wed Apr 29 01:44:43 +0000 2020,ç€¬æˆ¸å†…æµ·ã«è‡¨ã‚€ã€€ä¹³è…ºå¤–ç§‘åŒ»,"ã€#AACR20 COVID-19ãƒ—ãƒ¬ãƒŠãƒªãƒ¼ã®æ¦‚è¦ã¨æ„Ÿæƒ³, part 3ã€‘ç™ºè¡¨ãƒ‡ãƒ¼ã‚¿ã¯ã¾ã å°ã•ãã€é¸æŠãƒã‚¤ã‚¢ã‚¹ãŒã‚ã‚‹ã‹ã‚‚ã€‚å„å›½ã®çµŒé¨“ãŒã‹ãªã‚Šç•°ãªã£ã¦ã„ã‚‹ãŒã€ã“ã‚Œã¯ãƒ‡ãƒ¼ã‚¿ãƒ¼ã®åé›†æ–¹æ³•ãŒç•°ãªã‚‹ãŸã‚ã ã‚ã†ã‹ã€‚ ç–¾æ‚£åˆ¥ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã®å¿…è¦æ€§ã‚’æ„Ÿã˜ãŸã€‚ãŒã‚“æ‚£è€…å‘ã‘ã®æ„ŸæŸ“ã™ã‚‹ãƒªã‚¹ã‚¯ã‚’å®šç¾©ã™ã‚‹ã‚¢ãƒ«ã‚´ãƒªã‚ºãƒ ãŒå¿…è¦ã§ã‚ã‚‹ã€‚"
40,Wed Apr 29 01:45:39 +0000 2020,Alexandre JÃ¡come,"#AACR20 delighted to share that my small observation/formulaâ—is now published.ğŸ’¡Small but novel finding. 

ğŸ‘‰ğŸ¼What if you could calculate the ğŸ”¢CA-19-9/CEA ratio &amp; it could identify ğŸ§¬BRAFV600E MSS ğŸ†š MSI-High ğŸ†š Others. Simple, rapid, &amp; cheap. 

#CRCSM ğŸ“ƒhttps://t.co/7j0v23E2pq https://t.co/t359VmAK1n"
41,Wed Apr 29 01:45:58 +0000 2020,ç€¬æˆ¸å†…æµ·ã«è‡¨ã‚€ã€€ä¹³è…ºå¤–ç§‘åŒ»,"ã€#AACR20 COVID-19ã¨ãŒã‚“åŒ»ç™‚ã® ãƒ—ãƒ¬ãƒŠãƒªãƒ¼ã®æ¦‚è¦ã¨æ„Ÿæƒ³, part 1ã€‘
COVID-19ã®æ„ŸæŸ“ãƒªã‚¹ã‚¯ãŒé«˜ããªã£ãŸè¦å› ã€‚
- 3ãƒ¶æœˆä»¥å†…ã®åŒ–å­¦ç™‚æ³•
- PSãŒä½ã„ï¼šè™šå¼±ãªæ‚£è€…
- ç¤¾ä¼šçµŒæ¸ˆçš„åœ°ä½ãŒä½ã„
- è¡€æ¶²å­¦çš„æ‚ªæ€§è…«ç˜
- ç‰¹å®šã®ç¨®é¡ã®æ²»ç™‚æ³•ãŒç›®ç«‹ãŸãªã‹ã£ãŸã€‚å…ç–«ç™‚æ³•ã¯ãƒªã‚¹ã‚¯ã¨ã—ã¦å‡ºã¦ã“ãªã‹ã£ãŸã€‚"
42,Wed Apr 29 01:46:57 +0000 2020,ç€¬æˆ¸å†…æµ·ã«è‡¨ã‚€ã€€ä¹³è…ºå¤–ç§‘åŒ»,ç¢ºã‹ãªæƒ…å ±ã€€#CancerX
43,Wed Apr 29 01:47:32 +0000 2020,Sarah Temkin,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
44,Wed Apr 29 01:49:05 +0000 2020,Julian PÃ©rez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
45,Wed Apr 29 01:52:00 +0000 2020,OncLive.com,"Thanks for the coverage of our @SWOG trial results presented at #AACR20, @jasoncology and @OncLive!
https://t.co/av8vGk7toM via @onclive"
46,Wed Apr 29 01:52:22 +0000 2020,Ariella Hanker,Dr. Chris Abbosh's introduction very nicely framed the importance of intervention at the MRD stage. #LiquidBiopsy could allow us to shift the therapeutic window to when disease burden is earlier + guide targeted therapy selection. #AACR20
47,Wed Apr 29 01:52:24 +0000 2020,Dee Sparacio,"@ivybelkins @AACRFoundation Such a hot button for me too. People may have the ability to ""reduce their risk"" of cancer but true prevention is still not possible in most cases. To pretend otherwise is detrimental and creates stigma and shaming.  #WordsMatter #lcsm #bcsm #AACR20 #AACR2020"
48,Wed Apr 29 01:52:51 +0000 2020,Dee Sparacio,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
49,Wed Apr 29 01:53:04 +0000 2020,Ariella Hanker,Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG
50,Wed Apr 29 01:53:29 +0000 2020,Daniel Auclair,Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG
51,Wed Apr 29 01:53:30 +0000 2020,Angel Valencia V.,Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO
52,Wed Apr 29 01:53:58 +0000 2020,Angel Valencia V.,"At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG"
53,Wed Apr 29 01:54:38 +0000 2020,Susan G. Komen,New phase 2 trial results show that addition of Imprime PGG to pembrolizumab is a promising treatment for patients with #metastatic triple-negative #breastcancer #AACR20 https://t.co/6MZSEknwLh
54,Wed Apr 29 01:55:16 +0000 2020,MarÃ­a Luisa,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
55,Wed Apr 29 01:57:35 +0000 2020,@andypowell,"Our #AACR20 poster presentations are available on-demand. View research presentations by Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, and medical oncologist Mihaela Cristea, M.D.

Dr. Fong: https://t.co/taB7ae9TeQ
Dr. Cristea: https://t.co/XdWaJgt4tP https://t.co/VqLdJWiDx7"
56,Wed Apr 29 01:57:38 +0000 2020,NevaehMaya12,"RT cityofhope: Our #AACR20 poster presentations are available on-demand. View research presentations by Yuman Fong, M.D., chair of the Depâ€¦"
57,Wed Apr 29 01:59:47 +0000 2020,Daniel,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
58,Wed Apr 29 02:00:08 +0000 2020,josef (JosÃ© Armando),Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combinationâ€™s activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu
59,Wed Apr 29 02:01:41 +0000 2020,Manuel Cruz,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
60,Wed Apr 29 02:03:39 +0000 2020,Kowalyszyn Ruben,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
61,Wed Apr 29 02:04:36 +0000 2020,D. Russler-Germain,"Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:
â¬†ï¸ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op
#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1"
62,Wed Apr 29 02:05:03 +0000 2020,Yordan Monje Figueredo,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
63,Wed Apr 29 02:07:09 +0000 2020,Cubacoopera Jamaica,Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combinationâ€™s activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu
64,Wed Apr 29 02:08:29 +0000 2020,AlmeydaGeicon,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
65,Wed Apr 29 02:08:40 +0000 2020,Kellischultz1,"#AACR20 ğŸ’­I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose ğŸ©¸ğŸ§¬MRDâ•subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be highğŸ“ˆ. https://t.co/ltbTc4pISo"
66,Wed Apr 29 02:09:05 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"Dear Colleagues,
Thank you for a great couple of days of science, all of us at @OncoAlert ğŸš¨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2âƒ£.
Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC"
67,Wed Apr 29 02:09:09 +0000 2020,Stephanie Lheureux,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
68,Wed Apr 29 02:10:02 +0000 2020,OncLive.com,Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL @DanaFarber @AACR #lymsm #AACR20 https://t.co/sZhSb8dbdB
69,Wed Apr 29 02:10:09 +0000 2020,Christiana,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
70,Wed Apr 29 02:10:19 +0000 2020,Stephanie Lheureux,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
71,Wed Apr 29 02:10:36 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"Our @OncoAlert ğŸš¨Colleague @CharuAggarwalMD ğŸ‘©â€âš•ï¸from @PennCancer  Virtually Live at #AACR20 discussing globalğŸŒpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino ğŸ‡®ğŸ‡¹&amp; The French experience by @barlesi from @GustaveRoussy ğŸ‡«ğŸ‡·
Edited: @weoncologists https://t.co/yJXXuVGIJV"
72,Wed Apr 29 02:10:40 +0000 2020,pablo vazquez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
73,Wed Apr 29 02:11:59 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"Early detection at #AACR20: David Thiel @MayoClinic speaks about test to predict cancer and organ of origin w/cfDNA. ""Intention is to use in addition to testing based on screening guidelines (not on its own)"" -- wondering why not for all patients? #lcsm @lungcancer @EGFRResisters https://t.co/uzEWy6WNWR"
74,Wed Apr 29 02:12:22 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers
Edited: @weoncologists https://t.co/2rxks3qi8a"
75,Wed Apr 29 02:13:03 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"Technical challenges exist in using #liquidbiopsies to screen everyone for cancer, in addition to cost issues.  #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/V3xu4uyIHW"
76,Wed Apr 29 02:13:20 +0000 2020,Henry Cruz ğŸ‡µğŸ‡·ğŸ³ï¸â€ğŸŒˆ,"Check out this video by the amazing Dr. @CharuAggarwalMD. 

#OncoAlert 
#AACR20"
77,Wed Apr 29 02:13:49 +0000 2020,Henry Cruz ğŸ‡µğŸ‡·ğŸ³ï¸â€ğŸŒˆ,"As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert ğŸš¨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strongâ€¼ï¸ https://t.co/T8Cg4ptdzN"
78,Wed Apr 29 02:14:29 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20
79,Wed Apr 29 02:15:00 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"Our @OncoAlert ğŸš¨Colleague @LeciaSequist ğŸ‘©â€âš•ï¸of @MassGeneralNews Live from #AACR20 Discussing The Geometry Study and Zenith20. #LCSM @LungCancer 
Edited: @weoncologists https://t.co/U9ZPHynuZA"
80,Wed Apr 29 02:15:33 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"#OncoAlert #AACR20 More mature data emerging from China. This review by Dr. Zhang at Tongji in Wuhan discusses patients with cancer and #COVID19. Interesting to contrast these with data from US, Italy, Spain, France, etc - some trends just reflect patient populations served. https://t.co/5nxOc3BYb2"
81,Wed Apr 29 02:15:36 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"#OncoAlert #AACR20 Serial scans show #COVID19 related lung changes. Note the fibrosis emerging at day 25. Will long-term sequela impact respiratory function, quality of life? Will this vary by prior lung pathology, prior radiation, prior pneumonitis, etc? https://t.co/XrcRUiRe7e"
82,Wed Apr 29 02:15:40 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB"
83,Wed Apr 29 02:15:46 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert ğŸš¨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strongâ€¼ï¸ https://t.co/T8Cg4ptdzN"
84,Wed Apr 29 02:16:00 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y
85,Wed Apr 29 02:16:32 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"#AACR20 Dr. Domchekâ€™s discussion of PARPi #EMBRACA:

ğŸ— no OS with olaparib or talazoparib in #bcsm, but PFS and tolerability â¬†ï¸

âœ¨No diff by HR/TNBC, or by platinum, BUT benefit only w/ no chemo in MBC, not there 2nd/3rd line

ğŸ”€ crossover confounds OS, 32% got PARP @OncoAlert https://t.co/E9chuSZtnK"
86,Wed Apr 29 02:16:39 +0000 2020,Alejandro Bruno MejÃ­as IbÃ¡Ã±ez ğŸ’¯%ğŸ‡¨ğŸ‡º,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
87,Wed Apr 29 02:17:30 +0000 2020,Chan Cheah,"CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb"
88,Wed Apr 29 02:18:27 +0000 2020,Mathieu Rousseau,Cancer patients like triple-negative #breastcancer survivor @deb_silverman are among those most vulnerable to #COVID19: https://t.co/4M0pycC7i1 @washingtonpost #AACR20 #endcancer
89,Wed Apr 29 02:18:41 +0000 2020,Mathieu Rousseau,@IpshitaPrakash
90,Wed Apr 29 02:18:57 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr
91,Wed Apr 29 02:18:59 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2"
92,Wed Apr 29 02:19:02 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"#OncoAlert #AACR20 TAK-788 safety: At 160mg qd, G3+ AE in 40%, 25% dose reduction, 50% interruption. G3+ diarrhea 18%. Given the history of drugs here, does dose intensity correlate with DOR? I'm interested in G2 toxicities, which are very relevant here. Any QOL data? #LCSM https://t.co/32yxkSYdLW"
93,Wed Apr 29 02:19:43 +0000 2020,kyaw zin thein,"â€œThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,â€ says @DavidHongMD. 

Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer"
94,Wed Apr 29 02:19:52 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,David Huntsman discusses role of ctDNA/liquid biopsies &amp; interestingly the potential benefits of the uses are greatly increased due to #COVID19. #AACR20 #LCSM https://t.co/VofP7CmZXH
95,Wed Apr 29 02:20:24 +0000 2020,Kendri Brenan,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
96,Wed Apr 29 02:21:05 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,Tertiary lymphoid structure (TLS) formation in NSCLC may predict response to immunotherapy (durvalumab) thru interaction with tumor micro-environment. Dr. Sriram Sridhar from AstraZeneca #AACR2020 #AACR20 #LCSM https://t.co/ywMmlw63gL
97,Wed Apr 29 02:21:06 +0000 2020,Corina Mestre Vilaboy,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
98,Wed Apr 29 02:22:04 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment (DIRECT-On assay) is a simple blood test that can predict which pts respond to immunotherapy within first 6 months of starting immunotherapy @Barzin_ @Stanford @max_diehn #AACR2020 #AACR20 #LCSM https://t.co/9E8gRBzV8D
99,Wed Apr 29 02:23:42 +0000 2020,Modesto BaÃ±o,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
100,Wed Apr 29 02:23:48 +0000 2020,"Tullia Bruno, PhD",Yay B cells!
101,Wed Apr 29 02:23:50 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG"
102,Wed Apr 29 02:24:59 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS
103,Wed Apr 29 02:25:09 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,@theNCI is supporting #COVID19-related research efforts. Program announcements in this tweet. Please contact your program officer. #AACR2020 #AACR20 #LCSM https://t.co/1IKrsqoIJT
104,Wed Apr 29 02:25:10 +0000 2020,ChinaLeonard,Presentan resultados de ensayo clÃ­nico CIMAvax en congreso de AsociaciÃ³n para la InvestigaciÃ³n del CÃ¡ncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark
105,Wed Apr 29 02:25:32 +0000 2020,Bruno Larvol,#AACR20 more on PARPâ›”ï¸ #BRCA #DNA-Repair ğŸ§¬
106,Wed Apr 29 02:26:02 +0000 2020,Bruno Larvol,High yield data today at #AACR20 coming from my mentors and colleagues here at @MoffittNews #LCSM
107,Wed Apr 29 02:26:24 +0000 2020,Bruno Larvol,The @CancerResrch #TMB Harmonization Project aims to align across panel TMB values estimated with different commercial tests to ensure consistency across TMB values... this effort is key to help identify patients who are more likely to benefit from #immunotherapies #AACR20
108,Wed Apr 29 02:27:52 +0000 2020,Chris Lancashire,Very excited to see our #metanalysis from @ASCO_pubs #JCOGO presented at #AACR20 by @marinagarassino @HornLeora et al. #TERAVOLT team! @tm_parekh @ASCO @AACR @COVID19nCCC https://t.co/iOFHphGBZj
109,Wed Apr 29 02:28:05 +0000 2020,Chris Lancashire,Outstanding thread from @ADesaiMD #COVID19 #AACR20 @COVID19nCCC
110,Wed Apr 29 02:28:18 +0000 2020,Chris Lancashire,"Todayâ€™s #AACR20 presentation on #COVID19nCancer (and @CD_AACR paper) is the subject of a @lauriemcginley2 column. 
With a special cameo by @MDAndersonNews All Star physician scientist &amp; cancer survivor @deb_silverman #Bcsm @COVID19nCCC 
https://t.co/HiJ21w6Mq6"
111,Wed Apr 29 02:28:22 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,ctDNA measurement thru liquid biopsy over time (frm FLAURA study) predicts progression-free survival &amp; correlates w/ tumor size in EGFR-mutant NSCLC tx w/ osimertinib. Possibility fr monitoring during #COVID19? Dr. Martin Johnson frm Astra Zeneca #AACR2020 #AACR20 #LCSM https://t.co/5utKOMIMZc
112,Wed Apr 29 02:29:53 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb"
113,Wed Apr 29 02:30:01 +0000 2020,Bruno Larvol,.@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg
114,Wed Apr 29 02:32:48 +0000 2020,Sara Matar,"Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
115,Wed Apr 29 02:34:13 +0000 2020,Cancer Research Institute,Still catching up on #AACR20? CRI's @ArthurBrodsky shares highlights in #immunotherapy from Day 1. https://t.co/ep0pAZmNDb
116,Wed Apr 29 02:35:40 +0000 2020,"Nicolas Marcoux MD, FRCPC",Thanks to #AACR20 I donâ€™t feel depressed going through my twitter feed for the first time in weeks!
117,Wed Apr 29 02:36:18 +0000 2020,Linda McNeil Tantawi,"Our @OncoAlert ğŸš¨colleague @itsnot_pink live from #AACR20 discussing EMBRACA trial led by @MDAndersonNews .Advanced #breastcancer patients w/ #BRCA mutation, talazoparib did not see improved OS compared to #chemotherapy 
However did see improved QOLâ€¼ï¸#BCSM
edited: @weoncologists https://t.co/9aMaP9tnXK"
118,Wed Apr 29 02:36:55 +0000 2020,Rodrigo Nunes Cal,"As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert ğŸš¨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strongâ€¼ï¸ https://t.co/T8Cg4ptdzN"
119,Wed Apr 29 02:37:31 +0000 2020,Rodrigo Nunes Cal,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
120,Wed Apr 29 02:38:06 +0000 2020,Maray Pons,Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark
121,Wed Apr 29 02:38:44 +0000 2020,Eliane TÃ¡boas Merino,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
122,Wed Apr 29 02:38:59 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,Dear #AACR20 We're #OncoAlert âš•ï¸: @CharuAggarwalMD @Alfdoc2 @Tony_Calles @agrothey @JTrentMDPhD @ChristianRolfo @TiansterZhang @StephenVLiu @guiperini @prat_aleix @marklewismd @FAndreMD @weldeiry @BK_radiation @sharp_lena @DrSGraff @DrDanielHeng @MKnoll_MD @marinagarassino
123,Wed Apr 29 02:41:23 +0000 2020,Aniurka Ortiz,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
124,Wed Apr 29 02:43:45 +0000 2020,"Thomas LeBlanc, MD, MA, MHS, FAAHPM","#AACR20 Reminder that #WordsMatter. Just heard ""Many of our pts are metastatic."" Pts don't metastasize. Tumors do. Pts are not their disease so: ""Many of our pts have metastatic dz."" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP"
125,Wed Apr 29 02:44:34 +0000 2020,Bruno Larvol,"Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3"
126,Wed Apr 29 02:44:39 +0000 2020,Bruno Larvol,Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht
127,Wed Apr 29 02:46:00 +0000 2020,Bruno Larvol,Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM
128,Wed Apr 29 02:46:06 +0000 2020,mtmdphd,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0
129,Wed Apr 29 02:46:12 +0000 2020,Bruno Larvol,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
130,Wed Apr 29 02:55:14 +0000 2020,AACR,Todayâ€™s @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20
131,Wed Apr 29 02:55:41 +0000 2020,"Gladys Rodriguez,MD","Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch

Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. 

Now - how to enforce these guidelines?!

#BCSM #LCSM #MelSM"
132,Wed Apr 29 02:57:59 +0000 2020,Bruno Larvol,Mobo on the move: EGFR exon 20 insertions are a blindspot in targeted therapy options for #NSCLC. Yesterday #Takeda announced #FDA breakthrough for Mobocertinib (TAK-788) in ex20ins mNSCLC. Today at #AACR20 they encored their 2019 #ASCO phase 1/2 data showing a 43% ORR. #lcsm https://t.co/b8JjMMyRIf
133,Wed Apr 29 02:58:19 +0000 2020,Andres Cervantes,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
134,Wed Apr 29 02:59:40 +0000 2020,Kellischultz1,Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW
135,Wed Apr 29 03:00:04 +0000 2020,Camilo MorÃ³n,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
136,Wed Apr 29 03:00:23 +0000 2020,Alireza Mansouri,Still not where we need to be in stufying pts w #brainmets despite so much effort. We need pharma &amp; coop groups to include these pts! #btsm
137,Wed Apr 29 03:00:26 +0000 2020,ğŸ’–Dariana GonzÃ¡lez RodrÃ­guezğŸ’–,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
138,Wed Apr 29 03:02:13 +0000 2020,Kellischultz1,"#AACR20ğŸ‘‡ğŸ¼#TwitterPoll â¡ï¸ #COVID19 &amp; #Cancer #COVIDnCancer. 
Thoughts on minimizing surveillance visits or deciding on who could be spared or prioritized for chemo using #ctDNA #liquidbiopsies for #MinimalResidualDisease #MRD. Access programs available for #cancer â•home-drawğŸ©¸ğŸš‘"
139,Wed Apr 29 03:02:26 +0000 2020,MotorCentroCuba,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
140,Wed Apr 29 03:03:22 +0000 2020,RadiOncBOTjp,New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer
141,Wed Apr 29 03:03:45 +0000 2020,RadiOncBOTjp,#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS
142,Wed Apr 29 03:06:15 +0000 2020,"Omar Alhalabi, MD",Never understood that either! @AACR
143,Wed Apr 29 03:08:40 +0000 2020,Dr Caitlin Stewart,Nice thread on the #ctDNA session at virtual #AACR20- thanks @pratt_ed #liquidbiopsy #earlydetection
144,Wed Apr 29 03:10:03 +0000 2020,OncLive.com,TIL Therapy Elicits Encouraging Activity in Advanced NSCLC @MoffittNews @AACR #lcsm #AACR20 https://t.co/qxwMwtrTrR
145,Wed Apr 29 03:10:15 +0000 2020,AACR Foundation,Todayâ€™s @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20
146,Wed Apr 29 03:12:14 +0000 2020,guillermo perry moji,Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark
147,Wed Apr 29 03:13:20 +0000 2020,Let's Win! Pancreatic Cancer,Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG
148,Wed Apr 29 03:14:06 +0000 2020,CubacooperaQatar,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
149,Wed Apr 29 03:14:06 +0000 2020,City of Hope Surgery,"#AACR20 is now LIVE. Watch research presentations by City of Hope's Yuman Fong, M.D., the chief of the Department of Surgery; Kimlin Tam Ashing, Ph.D., the founding director of the Center of Community Alliance for Research &amp; Education, and medical oncologist Mihaela Cristea, M.D."
150,Wed Apr 29 03:15:26 +0000 2020,Seth Cohen,"#AACR20 is now LIVE. Watch research presentations by City of Hope's Yuman Fong, M.D., the chief of the Department of Surgery; Kimlin Tam Ashing, Ph.D., the founding director of the Center of Community Alliance for Research &amp; Education, and medical oncologist Mihaela Cristea, M.D."
151,Wed Apr 29 03:20:02 +0000 2020,Kevin Masukawa,"#AACR20ğŸ‘‡ğŸ¼#TwitterPoll â¡ï¸ #COVID19 &amp; #Cancer #COVIDnCancer. 
Thoughts on minimizing surveillance visits or deciding on who could be spared or prioritized for chemo using #ctDNA #liquidbiopsies for #MinimalResidualDisease #MRD. Access programs available for #cancer â•home-drawğŸ©¸ğŸš‘"
152,Wed Apr 29 03:20:42 +0000 2020,TaraMcG,Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW
153,Wed Apr 29 03:20:53 +0000 2020,Beth,New phase 2 trial results show that addition of Imprime PGG to pembrolizumab is a promising treatment for patients with #metastatic triple-negative #breastcancer #AACR20 https://t.co/6MZSEknwLh
154,Wed Apr 29 03:21:07 +0000 2020,ernesto lopez,Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combinationâ€™s activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu
155,Wed Apr 29 03:21:13 +0000 2020,"Wafik S. El-Deiry, MD, PhD, FACP","#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU"
156,Wed Apr 29 03:21:15 +0000 2020,Raciel ValdÃ©z,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
157,Wed Apr 29 03:25:21 +0000 2020,Katie Campbell,Still catching up on #AACR20? CRI's @ArthurBrodsky shares highlights in #immunotherapy from Day 1. https://t.co/ep0pAZmNDb
158,Wed Apr 29 03:28:11 +0000 2020,RadiOncBOTjp,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚"
159,Wed Apr 29 03:28:27 +0000 2020,Nowak Lab,.@Nowak_Lab &amp; @trotmanlab: Identification of the phosphatase PHLPP2â€™s role in controlling MYC stability could have implications for many cancers. JCBâ€™s cancer collection for #AACR20 (https://t.co/hgWqfffjWG) has new short summaries of articles: https://t.co/4RX37rq7jA https://t.co/Go7IWLoJZY
160,Wed Apr 29 03:29:00 +0000 2020,Dr. Deanna Attai,"Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer"
161,Wed Apr 29 03:29:29 +0000 2020,victor angel garcia,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
162,Wed Apr 29 03:29:35 +0000 2020,Abhilash Gavarraju,"Missed #COVID19nCancer plenary in #AACR20 @AACR?
Hereâ€™s a thread to catch up on all the fascinating global research presented by:
@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology"
163,Wed Apr 29 03:33:21 +0000 2020,Jun Gong,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
164,Wed Apr 29 03:33:48 +0000 2020,alyce,"Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer"
165,Wed Apr 29 03:34:10 +0000 2020,æ‘æœ¬@ åŒ»ç™‚Ã—IT / ãƒ‡ãƒ¼ã‚¿ã‚µã‚¤ã‚¨ãƒ³ã‚¹Ã—ãƒãƒ¼ã‚±ãƒ†ã‚£ãƒ³ã‚°ãƒªã‚µãƒ¼ãƒ,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚"
166,Wed Apr 29 03:36:47 +0000 2020,ã­ã“ğŸˆã¾ã‚‹,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚ https://t.co/OFppgUN3XK"
167,Wed Apr 29 03:39:03 +0000 2020,ã¯ã—ã¯ã—,"Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
168,Wed Apr 29 03:40:50 +0000 2020,ä¸–ç•Œã®åŒ»ç™‚ãƒ‹ãƒ¥ãƒ¼ã‚¹,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚"
169,Wed Apr 29 03:45:30 +0000 2020,SY Investing,"@ScienceMagazine @CellPressNews @MountSinaiNYC Potential therapies to treat #COVID19 hyperinflammation. #CytokineStorm

Targets: GM-CSF, IL-17, IL-23, TNF, IL-6, JAK &amp; IL-1

Companies: $IMAB $HGEN $GSK $RHHBY $SNY $REGN $EUSA $NVS $INCY $AMGN $PFE $LLY $ABBV $BMY $ALPMY $ALXN $KNSA $SOBI $JNJ @Roivant

https://t.co/bLGxRlKKu1"
170,Wed Apr 29 03:48:49 +0000 2020,Marty Makary,This poster was actually the one I was watching when it struck me how awesome the individual poster video format is ğŸ˜‰. Nicely presented @benweinbergmd #AACR20 #PancreaticCancer
171,Wed Apr 29 03:48:58 +0000 2020,Todd Druley,"We are aiming to expand #PrecisionOncology into early-stage cancer, when #cancer is typically easier to cure. #AACR20 #AACR2020 https://t.co/dTrjwWZqge"
172,Wed Apr 29 03:49:22 +0000 2020,Todd Druley,"We announced new #MRD surveillance data from the #TRACERx collaboration with @uclcancer, @TheCrick &amp; @CR_UK at #AACR20. Read the release: https://t.co/9W4ezkbVKv #AACR2020 https://t.co/M2T6pUSaDN"
173,Wed Apr 29 03:57:53 +0000 2020,Angela Snow,"@SeanSachdevMD @subatomicdoc @_ShankarSiva @SBRT_CR @theabzlab @Prof_Nick_James @DrSpratticus I love the virtual format! My PI has funds to send me to conferences every 3 years. I've attended 2 conferences this week alone: #AACR20 and #TAGC20 The questions are lot better, since the moderator can group related questions and participants can ""vote up"" questions they like."
174,Wed Apr 29 03:59:09 +0000 2020,é¬¼ç•œãƒ¡ã‚¬ãƒ,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚"
175,Wed Apr 29 03:59:59 +0000 2020,Yuri A. Gala LÃ³pez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
176,Wed Apr 29 04:01:35 +0000 2020,chawnte,"Next ""new drug on the horizon"" is an oral SERD (Selective Estrogen Receptor Degrader), GDC-9545. Achieved same efficacy as other SERDs, but at a lower dose.

Currently recruiting patients with #ER+ #MBC. 

#BCSM #AACR20 
https://t.co/7aWgt2Bv60"
177,Wed Apr 29 04:04:47 +0000 2020,Tant de Lys,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚ https://t.co/OFppgUN3XK"
178,Wed Apr 29 04:04:52 +0000 2020,Tant de Lys,New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer https://t.co/41pUGEvmeG
179,Wed Apr 29 04:05:09 +0000 2020,Thereâ€™s Only One Sweden,"For the first time, a blood test helped doctors find and treat cancers in seemingly healthy people https://t.co/iR9ZLFJNTj via @sheridan_kate #AACR20"
180,Wed Apr 29 04:10:03 +0000 2020,OncLive.com,COVID-19: Practical and Immuno-Oncology Insight in Melanoma and Beyond @PAscierto @AACR #coronavirus #COVID19 #AACR20 https://t.co/XgQ8GsU8I6
181,Wed Apr 29 04:11:36 +0000 2020,Sunrise Relay,We continue to learn about impact of #COVID19 on #cancer patients. A number of studies reported at @AACR today continue to expand our knowledge. Now we need a coherent picture. What is clear: many patients with #cancer develop serious illness because of their disease/treatment
182,Wed Apr 29 04:12:18 +0000 2020,Nicole Kuderer,That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y
183,Wed Apr 29 04:19:08 +0000 2020,"Enlightening ""#StayHome"" Results",#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
184,Wed Apr 29 04:20:18 +0000 2020,Roberta,Todayâ€™s @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20
185,Wed Apr 29 04:20:41 +0000 2020,"Irene Helenowski, Ph.D.","#AACR20 starts as a virtual meeting with 54,000 ppl

An important meeting held in this format:
Should others follow?

ğŸ‘‰No facility/flight expenses
ğŸ‘‰Reduced environment impact
ğŸ‘‰Reduce $ to register
ğŸ‘‰More can participate globally
ğŸ‘‰More important information disseminated https://t.co/OPSjKPNWsG"
186,Wed Apr 29 04:21:56 +0000 2020,Anne,"#AACR20 Reminder that #WordsMatter. Just heard ""Many of our pts are metastatic."" Pts don't metastasize. Tumors do. Pts are not their disease so: ""Many of our pts have metastatic dz."" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP"
187,Wed Apr 29 04:23:13 +0000 2020,Instituto Finlay,"Avances de #Vacuna cubana contra el cÃ¡ncer, fueron presentados en colaboraciÃ³n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituciÃ³n, existe un convenio de colaboraciÃ³n que estÃ¡ dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB"
188,Wed Apr 29 04:23:34 +0000 2020,Dr Ivan R GonzÃ¡lez,#Cancer | Uso de #olaparib para cÃ¡ncer de prÃ³stata metastÃ¡sico resistente a castraciÃ³n.
189,Wed Apr 29 04:24:16 +0000 2020,OncoAlert,"Check out this video by the amazing Dr. @CharuAggarwalMD. 

#OncoAlert 
#AACR20"
190,Wed Apr 29 04:24:25 +0000 2020,OncoAlert,#Metabolism (Oncometabolites) and #DDR as targets to treat #cancer . #AACR20 #OncoAlert https://t.co/58jvSF5Skd
191,Wed Apr 29 04:24:29 +0000 2020,OncoAlert,"Dear Colleagues,
Thank you for a great couple of days of science, all of us at @OncoAlert ğŸš¨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2âƒ£.
Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC"
192,Wed Apr 29 04:26:07 +0000 2020,Judy Boughey,"#AACR20 plenary on #PARPâ›”ï¸â•#immunotherapy resulted in not only â¬†ï¸pathCR (pCR) but also another important measure: residual cancer burden (RCB). 
âœ…HER2â–20%â¡ï¸37%
âœ…HRâ–HER2â–27%â¡ï¸47%
âœ…HRâ•HER2â–14%â¡ï¸28%
#OncoAlert https://t.co/DraYXx4vwL"
193,Wed Apr 29 04:28:05 +0000 2020,ãã‚ãŠğŸ”®ãƒªãƒ³ã‚«ãƒ¼,Syndax announces positive preclinical profile and initial phase 1 data for the Menin inhibitor SNDX-5613 in adults with relapsed or refractory acute leukemias. #leukemia #AACR20 https://t.co/h4f8uYnZUE https://t.co/g51o4AXVUq
194,Wed Apr 29 04:29:44 +0000 2020,Boris Hadaschik,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
195,Wed Apr 29 04:36:10 +0000 2020,Bruno Larvol,New prospective data on outcomes with IO for NSCLC based on STK11 and KEAP1 status. Certainly limitations with only subset with available NGS results. Some of my best IO responders have been 2 STK11-mut patients. Not ready to skip IO for these patients yet. #AACR20 #LCSM https://t.co/1T8Mwt9hTu
196,Wed Apr 29 04:36:45 +0000 2020,Patricia JuÃ¡rez Camacho,"Are all viruses bad? @Mark_Cobbold, a scientist &amp; VP Oncology Early Discovery, breaks down one of the most exciting areas of cancer research: viruses that are designed to infect and kill cancer cells. #SciencefromAtoZ #AACR20 https://t.co/Q2Iix6vk6y"
197,Wed Apr 29 04:36:54 +0000 2020,ã®ãã¿ã®ä¼š,The latest The ã®ãã¿ã®ä¼š Daily! https://t.co/D5S09IzSL5 Thanks to @cocoha9608 @outsidervoice @cancer_navi #ä¹³ãŒã‚“ #aacr20
198,Wed Apr 29 04:37:17 +0000 2020,Chang-il Hwang,Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG
199,Wed Apr 29 04:37:27 +0000 2020,Bruno Larvol,TAK-788 ph2 in pts with EGFR exon 20 insertions treated at 160mg. ORR 43%. Responses seen in pretreated TKI/IO pts as well. Most common AE is GI tox. Food instructions has been updated in this study to improve GI tox. #AACR20 https://t.co/NJOR4A8xK5
200,Wed Apr 29 04:37:49 +0000 2020,ä¸€ä»‹ã®æ”¾å°„ç·šç§‘åŒ»,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚"
201,Wed Apr 29 04:40:34 +0000 2020,PorteusesPIP,"ğŸ“¢ Pr Fabrice @barlesi @GustaveRoussy a prÃ©sentÃ© en plÃ©niÃ¨re #Covid19etCancer du congrÃ¨s #AACR20 une analyse prÃ©coce de la situation et la maniÃ¨re dont Gustave Roussy sâ€™est adaptÃ© avec agilitÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie de #covid19.

Lire le communiquÃ© : https://t.co/VPFdDJgHol"
202,Wed Apr 29 04:40:48 +0000 2020,AJ K-Alar,Todayâ€™s @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20
203,Wed Apr 29 04:42:53 +0000 2020,Dr Ivan R GonzÃ¡lez,"At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG"
204,Wed Apr 29 04:43:06 +0000 2020,Bruno Larvol,A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24
205,Wed Apr 29 04:44:11 +0000 2020,Bruno Larvol,Clinical activity of TAK-788 - 160 mg qd recommended dose for Phase II #AACR20 https://t.co/BbjUFD1vJD
206,Wed Apr 29 04:45:13 +0000 2020,Lehti Lab,"Read @TrendsinPharma ""The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers"" by Muranen (@tarumurmur) and colleagues - https://t.co/SoHGL2ngoO - #CellPressOncology #AACR20"
207,Wed Apr 29 04:47:46 +0000 2020,Dr Ivan R GonzÃ¡lez,"#COVID19 | Un dato bastante e importante  que comparte @LizCancerHealth, en la Ã¡rea #NYC parece existir un Ã­ndice de mortalidad mÃ¡s alto en #latinos y #afroamericanos que caucÃ¡sicos y asiÃ¡ticos, #QuedateEnCasa"
208,Wed Apr 29 04:47:55 +0000 2020,Myriam R Couso,#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF
209,Wed Apr 29 04:48:25 +0000 2020,Marcel Massoud,#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF
210,Wed Apr 29 04:49:30 +0000 2020,Julie Oniszczuk,"Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
211,Wed Apr 29 04:50:23 +0000 2020,EmbaCubaJapon,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
212,Wed Apr 29 04:51:31 +0000 2020,Elad Sharon,"First up, Dr Zhang presents the experience of taking care of patients with COVID in Wuhan, China.  Lung cancer was the most common cancer seen in patients, but multiple other cancers were noted. #AACR20 https://t.co/LKBTvEtg5w"
213,Wed Apr 29 04:51:47 +0000 2020,Huy Ma,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0
214,Wed Apr 29 04:53:27 +0000 2020,Filip Janku,"â€œThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,â€ says @DavidHongMD. 

Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer"
215,Wed Apr 29 04:53:57 +0000 2020,Filip Janku,"Combining the immunotherapy drug durvalumab with chemotherapy achieved improved response in advanced #ovariancancer patients, according to a recent MD Anderson-led study, presented at #AACR20 by our @ShannonWestin:  https://t.co/NXUYjKX0oE #CancerMoonshot #endcancer"
216,Wed Apr 29 04:53:58 +0000 2020,Dr Ivan R GonzÃ¡lez,#Cancer #COVID19 | @chulkimMD comparte algunos puntos importantes a considerar sobre el #Cancer a partir de la pandemia de la autorÃ­a del Dr. Louis Voight
217,Wed Apr 29 04:54:55 +0000 2020,Filip Janku,Cancer patients like triple-negative #breastcancer survivor @deb_silverman are among those most vulnerable to #COVID19: https://t.co/4M0pycC7i1 @washingtonpost #AACR20 #endcancer
218,Wed Apr 29 04:55:04 +0000 2020,Filip Janku,"â€œThese variations highlight the need for continued study of #brainmetastases in order to better understand them and potentially find therapeutic targets,â€ says our Dr. Andy Futreal: https://t.co/0qEDHCjyUS #AACR20 #endcancer"
219,Wed Apr 29 04:55:18 +0000 2020,Filip Janku,The Phase III EMBRACA clinical trial led by our @JenniferLitton showed advanced #breastcancer patients taking talazoparib had better overall health for longer than those on chemotherapy: https://t.co/BdTotwoukm #AACR20 #bcsm #endcancer
220,Wed Apr 29 04:55:28 +0000 2020,Dr Ivan R GonzÃ¡lez,#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr
221,Wed Apr 29 04:56:57 +0000 2020,Dr Ivan R GonzÃ¡lez,"#Covid19 and #Cancer lecture in #AACR20 . #OncoAlert
âœ…No anti-cancer treatment associated with higher mortality
âœ…Patients treateted with ICI wer NOT more succeptible to infection
âœ…patchy consolidation risk factor for severe events
âœ…donÂ´t forget cancer tx. https://t.co/zVXpumDKIv"
222,Wed Apr 29 04:58:22 +0000 2020,Dr Ivan R GonzÃ¡lez,#Cancer #COVID19 | Algunos puntos impotentes a considerar del #AACR20 sobre el manejo oncolÃ³gico durante #COVID__19
223,Wed Apr 29 04:59:45 +0000 2020,Michael Fisch MD MPH,.@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg
224,Wed Apr 29 05:00:17 +0000 2020,Muzaffar Qazilbash,Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention @ScienceMagazine  #AACR20 #cancerscreening https://t.co/fWAVjO6TUB
225,Wed Apr 29 05:01:18 +0000 2020,Muzaffar Qazilbash,"DNA blood test spots cancers in seemingly cancer-free women, but also produces false alarms #AACR20 #cancerscreening https://t.co/1SOMVbRPU4"
226,Wed Apr 29 05:01:42 +0000 2020,Dr Ivan R GonzÃ¡lez,#COVID19 | Hoy mÃ¡s que nunca es crucial compartir nuestra informaciÃ³n con la comunidad mÃ©dica y el trato cercano con nuestros pacientes. #Cancer
227,Wed Apr 29 05:01:47 +0000 2020,Angel4U,"â€œOur preclinical data suggest that IPN60090 may be effective in underserved groups of patients who need better treatment options,â€ says our Dr. Jeffrey Kovacs: https://t.co/nAcAdjEdXQ #AACR20 #CancerMoonshot #endcancer"
228,Wed Apr 29 05:01:54 +0000 2020,Angel4U,Our phase II study of combination of durvalumab and standard chemotherapy in #ovariancancer will be presented today at the virtual #AACR20 meeting!  #gyncsm #CancerMoonshot #endcancer
229,Wed Apr 29 05:03:20 +0000 2020,Dr Ivan R GonzÃ¡lez,"Some of the outstanding questions in #ctDNA #AACR20 by Dr Huntsman @UBC - longitudinal impact, sensitivity, financial burden, and of course some of the advantages arising under the lens of #COVID19 https://t.co/kLg08Cuvce"
230,Wed Apr 29 05:03:32 +0000 2020,Gautam Kollu,Detecting cancer early matters. Kudos to the team at Thrive and @MichaelPellini  for their prospective trial showing that a series of blood tests with low false positive rates can safely enable earlier detection of multiple cancers. Congrats! #aacr20
231,Wed Apr 29 05:09:57 +0000 2020,Pedro Alfredo Castillo,"Avances de #Vacuna cubana contra el cÃ¡ncer, fueron presentados en colaboraciÃ³n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituciÃ³n, existe un convenio de colaboraciÃ³n que estÃ¡ dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB"
232,Wed Apr 29 05:10:03 +0000 2020,OncLive.com,Blood Test Is Feasible for Early Detection Across Multiple Cancers @HopkinsMedicine @AACR #AACR20 https://t.co/4N1346mbwQ
233,Wed Apr 29 05:10:38 +0000 2020,Yuri A. Gala LÃ³pez,"Avances de #Vacuna cubana contra el cÃ¡ncer, fueron presentados en colaboraciÃ³n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituciÃ³n, existe un convenio de colaboraciÃ³n que estÃ¡ dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB https://t.co/V35FL0gi6u"
234,Wed Apr 29 05:12:01 +0000 2020,cunmarket.com,"DNA blood test spots cancers in seemingly cancer-free women, but also produces false alarms #AACR20 #cancerscreening https://t.co/1SOMVbRPU4"
235,Wed Apr 29 05:12:24 +0000 2020,cunmarket.com,Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention @ScienceMagazine  #AACR20 #cancerscreening https://t.co/fWAVjO6TUB
236,Wed Apr 29 05:13:39 +0000 2020,cunmarket.com,@MethodistHosp @sloan_kettering @MountSinaiNYC @DanaFarber @KimmelCancerCtr https://t.co/Fthgoi57Io
237,Wed Apr 29 05:13:58 +0000 2020,OncoAlert,These are great numbers @AACR - and so are the blockbuster number of residents. Great planning in short order to make #AACR20 virtual.
238,Wed Apr 29 05:17:24 +0000 2020,Julien Defontaines,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
239,Wed Apr 29 05:17:38 +0000 2020,Julien Defontaines,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
240,Wed Apr 29 05:19:35 +0000 2020,Andy Latchford,The results of our Naproxen in #LynchSyndrome Phase I clinical trial presented today at #AACR20 @AACR Naproxen induced activation of resident immune cells in the normal colorectal mucosa #immuneinterception ğŸ‘‡
241,Wed Apr 29 05:20:28 +0000 2020,Adid Naranjo Soto,"Avances de #Vacuna cubana contra el cÃ¡ncer, fueron presentados en colaboraciÃ³n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituciÃ³n, existe un convenio de colaboraciÃ³n que estÃ¡ dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB https://t.co/V35FL0gi6u"
242,Wed Apr 29 05:21:30 +0000 2020,Kristi Rosa,One more time for the folks in the backâ€” #WordsMatter
243,Wed Apr 29 05:21:53 +0000 2020,Kristi Rosa,"Missed #COVID19nCancer plenary in #AACR20 @AACR?
Hereâ€™s a thread to catch up on all the fascinating global research presented by:
@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology"
244,Wed Apr 29 05:22:26 +0000 2020,"Pierre Blanchard, MD",Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO
245,Wed Apr 29 05:25:32 +0000 2020,OnkoIv,Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc
246,Wed Apr 29 05:25:55 +0000 2020,Arnaud Bayle,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
247,Wed Apr 29 05:26:21 +0000 2020,Negina Gencheva,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
248,Wed Apr 29 05:29:32 +0000 2020,Kristi Rosa,"Excited to have @BrendonStilesMD with us tmrw as we continue our discussions on management of #LungCancer during #COVID19, including updates from #AACR20 
@StephenVLiu @JackWestMD @n8pennell @OncLive @ginacolumbusonc #LCSM @OncoAlert"
249,Wed Apr 29 05:29:57 +0000 2020,Vivian Montero Alejo,Presentan resultados de ensayo clÃ­nico CIMAvax en congreso de AsociaciÃ³n para la InvestigaciÃ³n del CÃ¡ncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark
250,Wed Apr 29 05:30:16 +0000 2020,Kristi Rosa,Blood Test Is Feasible for Early Detection Across Multiple Cancers @HopkinsMedicine @AACR #AACR20 https://t.co/4N1346mbwQ
251,Wed Apr 29 05:30:25 +0000 2020,Kristi Rosa,COVID-19: Practical and Immuno-Oncology Insight in Melanoma and Beyond @PAscierto @AACR #coronavirus #COVID19 #AACR20 https://t.co/XgQ8GsU8I6
252,Wed Apr 29 05:30:28 +0000 2020,Kristi Rosa,TIL Therapy Elicits Encouraging Activity in Advanced NSCLC @MoffittNews @AACR #lcsm #AACR20 https://t.co/qxwMwtrTrR
253,Wed Apr 29 05:30:33 +0000 2020,Kristi Rosa,Positive Safety Profile Reported for Atezolizumab/Axi-Cel Combo in DLBCL @DanaFarber @AACR #lymsm #AACR20 https://t.co/sZhSb8dbdB
254,Wed Apr 29 05:30:48 +0000 2020,ESMO - Eur. Oncology,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
255,Wed Apr 29 05:30:49 +0000 2020,Kristi Rosa,Adopting Multidisciplinary and Evolving Care Plans Are Essential to Treat Cancer and COVID-19 @Hospital12deOct @AACR #COVID19 #coronavirus #AACR20 https://t.co/8ZAKK5KC40
256,Wed Apr 29 05:30:53 +0000 2020,Kristi Rosa,"Clinical Factors Predict Deterioration Among Patients With Cancer, COVID-19 @barlesi @GustaveRoussy @AACR #coronavirus #COVID19 #AACR20 https://t.co/FDtUuutt8w"
257,Wed Apr 29 05:30:56 +0000 2020,Kristi Rosa,Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL @NCIResearchCtr @AACR #AACR20 #leusm https://t.co/9i0ji0YNCf
258,Wed Apr 29 05:31:07 +0000 2020,Kristi Rosa,Novel Innate Immune Activator Boosts PD-1 Inhibition Responses in mTNBC @JohnWayneCI @SaintJohns2 @AACR #bcsm #AACR20 https://t.co/cdaVe8HCdV
259,Wed Apr 29 05:31:20 +0000 2020,ESMO - Eur. Oncology,"cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies. https://t.co/MabdIDGsFI"
260,Wed Apr 29 05:33:08 +0000 2020,Ryan Noor,This was the structural disclosure many were waiting for at #AACR20 @AACR: Matthew LaMarche of @NovartisScience raising the curtain for clinical SHP2 inhibitor #TNO155. Structurally quite distinct from previous tool SHP099 in order to address phototox &amp; off-target liabilities https://t.co/iOeyie4nia
261,Wed Apr 29 05:33:30 +0000 2020,Hugo Arasanz,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
262,Wed Apr 29 05:34:43 +0000 2020,ESMO - Eur. Oncology,#AACR20 Here is the link to the paper published in Annals of Oncology by Zhang et al on the clinical characteristics of patients with cancer infected by #COVID19 https://t.co/qSrRxJLMvY https://t.co/STAKx1RkSR
263,Wed Apr 29 05:35:15 +0000 2020,Sanjay Mukhopadhyay,"Iâ€™m with Joshua. This pathologic obsession with secrecy in medical conferences is so 20th century.

Isnâ€™t the goal to make great medical breakthroughs and other key medical information freely available to everyone as quickly as possible using all available technology?"
264,Wed Apr 29 05:35:33 +0000 2020,Tina Han,"Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:
â¬†ï¸ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op
#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1"
265,Wed Apr 29 05:38:42 +0000 2020,Clare Turnbull Dr/Prof #FBPE,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
266,Wed Apr 29 05:42:11 +0000 2020,Melinda V Inman,TIL Therapy Elicits Encouraging Activity in Advanced NSCLC https://t.co/7xPmSfSQZA #AACR20 #LCSM
267,Wed Apr 29 05:42:18 +0000 2020,Melinda V Inman,FDA Grants Mobocertinib (TAK-788) Breakthrough Designation for EGFR Exon 20-Mutant NSCLC https://t.co/VbM00DvgxX #AACR20 #LCSM
268,Wed Apr 29 05:43:02 +0000 2020,Joan Climent,"Check recent content @NatureCancer
 about #ctDNA and #LiquidBiopsy in cancer:

- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!

https://t.co/OMPFaRGU65
https://t.co/SXvHYm5Hmw
https://t.co/e26wYMedBV
https://t.co/CErTHIOYvA

#AACR20 https://t.co/agOl6k5Zfh"
269,Wed Apr 29 05:43:46 +0000 2020,LUIS REY,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
270,Wed Apr 29 05:43:54 +0000 2020,Jean-baptiste AssiÃ©,"Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
271,Wed Apr 29 05:49:59 +0000 2020,Journal of Cancer Science and Research,"Journal of Cancer Science and Research#Submitmanuscript#COVID-19
https://t.co/f5JF352O5r"
272,Wed Apr 29 05:50:18 +0000 2020,Clare Turnbull Dr/Prof #FBPE,"cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies."
273,Wed Apr 29 05:53:22 +0000 2020,Lars Ole Haustedt,Wau lots of fluorine any F polar interactions described? Or â€onlyâ€œ metabolic stability? Looks exciting
274,Wed Apr 29 05:57:18 +0000 2020,mehmet ali uÃ§ar,"CONGRESS | #AACR20 | Jonathan Pachter discusses the synergistic action of the dual PI3K inhibitor, duvelisib, with PD-1 blockage in solid tumor and lymphoma models. A clinical trial of duvelisib + nivolumab in tFL and Richterâ€™s transformation is ongoing #lymsm https://t.co/aJwPboXCDS"
275,Wed Apr 29 05:59:22 +0000 2020,"Kevin Carvalho, PhD","CONGRESS | #AACR20 | Jonathan Pachter discusses the synergistic action of the dual PI3K inhibitor, duvelisib, with PD-1 blockage in solid tumor and lymphoma models. A clinical trial of duvelisib + nivolumab in tFL and Richterâ€™s transformation is ongoing #lymsm https://t.co/aJwPboXCDS"
276,Wed Apr 29 06:00:44 +0000 2020,Symplur Hashtags,Today's Health Conferences: #AACR20 #depression #aacr2020 https://t.co/YnZewsLKhm #hcsm
277,Wed Apr 29 06:02:43 +0000 2020,Rafael AgustÃ­n Merino Betancourt,Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combinationâ€™s activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu
278,Wed Apr 29 06:03:49 +0000 2020,PATRIA AmÃ©rica Latina y el CaribeğŸ‡³ğŸ‡®ğŸ‡¨ğŸ‡ºğŸ‡»ğŸ‡ªâ¤ğŸ–¤ğŸ‘Š,"Avances de #Vacuna cubana contra el cÃ¡ncer, fueron presentados en colaboraciÃ³n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituciÃ³n, existe un convenio de colaboraciÃ³n que estÃ¡ dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB"
279,Wed Apr 29 06:03:51 +0000 2020,Pau Frias Ruiz,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
280,Wed Apr 29 06:08:00 +0000 2020,Eva Schumacher-Wulf,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
281,Wed Apr 29 06:10:02 +0000 2020,OncLive.com,WATCH: Dr. DiBiase on Data With DM-CHOC-PEN/Radiation in Cancers Involving the CNS @WeillCornell @nyphospital @AACR #AACR20 https://t.co/onAWDHZzuu
282,Wed Apr 29 06:13:10 +0000 2020,"Angel Panizo MD, PhD ğŸ‡ªğŸ‡¸ ğŸ”¬","Iâ€™m with Joshua. This pathologic obsession with secrecy in medical conferences is so 20th century.

Isnâ€™t the goal to make great medical breakthroughs and other key medical information freely available to everyone as quickly as possible using all available technology?"
283,Wed Apr 29 06:13:34 +0000 2020,Dominique Valteau,"ğŸ“¢ Pr Fabrice @barlesi @GustaveRoussy a prÃ©sentÃ© en plÃ©niÃ¨re #Covid19etCancer du congrÃ¨s #AACR20 une analyse prÃ©coce de la situation et la maniÃ¨re dont Gustave Roussy sâ€™est adaptÃ© avec agilitÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie de #covid19.

Lire le communiquÃ© : https://t.co/VPFdDJgHol"
284,Wed Apr 29 06:13:48 +0000 2020,Pilar Garrido,#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF
285,Wed Apr 29 06:14:41 +0000 2020,OncoAlert,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
286,Wed Apr 29 06:14:48 +0000 2020,Colm O'Rourke,"cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies. https://t.co/MabdIDGsFI"
287,Wed Apr 29 06:20:50 +0000 2020,UroUpdate,#AACR20 news: No improvement in metastatic #CRPC outcomes with addition of #atezolizumab to #enzalutamide - phase 3 IMbassador250 data reported by @ChrisSweens1 (of @DanaFarber) #immunotherapy @PCF_Science @DanaFarberNews @uroupdate https://t.co/APLniIkJyC
288,Wed Apr 29 06:21:36 +0000 2020,Axel Merseburger,#AACR20 news: No improvement in metastatic #CRPC outcomes with addition of #atezolizumab to #enzalutamide - phase 3 IMbassador250 data reported by @ChrisSweens1 (of @DanaFarber) #immunotherapy @PCF_Science @DanaFarberNews @uroupdate https://t.co/APLniIkJyC
289,Wed Apr 29 06:22:03 +0000 2020,Martin Cabero,"CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb"
290,Wed Apr 29 06:24:59 +0000 2020,Lisa92,"#COVID19 #AACR20 #LCSM
TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.
198 pts evaluated with 34.6% of death rate.
Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi"
291,Wed Apr 29 06:25:19 +0000 2020,Marcia GonzÃ¡lez GuzmÃ¡n,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
292,Wed Apr 29 06:26:22 +0000 2020,Tom Newsom-Davis,"Dr Marina Garassino @marinagarassino presenting data from #TERAVOLT evaluating #COVID19 and lung cancer #LCSM 
Results overlapping with our own institutional experience recently spread via #SoMe #AACR20 @AACR @OncoAlert #OncoAlert @IASLC @gecp_org https://t.co/zcglqIyYow"
293,Wed Apr 29 06:26:58 +0000 2020,Tom Newsom-Davis,"#AACR20 #LCSM #EGFR
Disappointing results of #Poziotinib in 2L+ EGFR Exon20ins (n=115) by @LeXiuning
ORR: 15% | mPFS: 4.2 m 
TRAEs â‰¥ 3: 63% (72/114) w/ 68% dose-reduction!
Toxic profile w/ limited activity for being a good TKI. 
What to expect from Ph3? Not much else 
#OncoAlert https://t.co/ihvbaL7gZU"
294,Wed Apr 29 06:28:08 +0000 2020,Tom Newsom-Davis,"#COVID19 #AACR20 #LCSM
TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.
198 pts evaluated with 34.6% of death rate.
Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi"
295,Wed Apr 29 06:29:19 +0000 2020,Tom Newsom-Davis,"This is a critical slide - capmatinib has clear efficacy in the brain.  We knew it got in, but the fact that we are seeing IC responses is very important.  As I mentioned above, this draws an important distinction from crizotinib where CNS efficacy is rare. #AACR20 #LCSM https://t.co/QFd0uHSgU3"
296,Wed Apr 29 06:33:35 +0000 2020,Repositive.io,That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y
297,Wed Apr 29 06:33:47 +0000 2020,Repositive.io,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
298,Wed Apr 29 06:33:53 +0000 2020,Repositive.io,"Missed #COVID19nCancer plenary in #AACR20 @AACR?
Hereâ€™s a thread to catch up on all the fascinating global research presented by:
@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology"
299,Wed Apr 29 06:34:03 +0000 2020,Repositive.io,"Coinciding with the #COVID19nCancer session at #AACR20, @CD_AACR has published the largest peer reviewed series (thus far) of #COVID19 in cancer patients (N=105 from China). 
Overall, a higher rate of complications is seen across the board. @tmprowell 
https://t.co/sgH7lEi0z6 https://t.co/32VGCKwx2u"
300,Wed Apr 29 06:34:24 +0000 2020,Repositive.io,#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd
301,Wed Apr 29 06:34:45 +0000 2020,Repositive.io,Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM
302,Wed Apr 29 06:35:03 +0000 2020,SOLTI,#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd
303,Wed Apr 29 06:35:38 +0000 2020,Repositive.io,Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO
304,Wed Apr 29 06:35:50 +0000 2020,Repositive.io,A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24
305,Wed Apr 29 06:35:58 +0000 2020,Repositive.io,"Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
306,Wed Apr 29 06:36:15 +0000 2020,Repositive.io,"This is a critical slide - capmatinib has clear efficacy in the brain.  We knew it got in, but the fact that we are seeing IC responses is very important.  As I mentioned above, this draws an important distinction from crizotinib where CNS efficacy is rare. #AACR20 #LCSM https://t.co/QFd0uHSgU3"
307,Wed Apr 29 06:36:35 +0000 2020,Repositive.io,"Toxicity of capmatinib is generally pretty mild, and not dissimilar from with crizotinib.  We gain CNS efficacy without cost in the form of toxicity.  Hopefully patients will have access to this agent soon. It is currently under priority review at the FDA #AACR20 #LCSM https://t.co/s4f8Gble9o"
308,Wed Apr 29 06:36:36 +0000 2020,ProfJohnCrown,Important. We started doing it when pandemic came to Ireland.
309,Wed Apr 29 06:37:10 +0000 2020,Repositive.io,"What we learned at #AACR20 Day 1: 1. You CAN get 48,000+ participants to register for the worldâ€™s largest webinar (canâ€™t wait to see demographic data);
2. KRAS is Undrugged (*yet*), not Undruggable;
3. BRAF is the ultimate Hydra;           4. @AACR really came throughğŸ‘"
310,Wed Apr 29 06:38:30 +0000 2020,FabriceAndre,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
311,Wed Apr 29 06:39:34 +0000 2020,Conchi Andujar,@OncoAlert @BenWestphalen @weoncologists #AACR20 ğŸ‘†ğŸ¼#BRAF - one of my patients recently sent me this illustrating from a recent review the diversity of tumor types in which #BRAF mutations are seen as well as the spectrum of mutations (V600E ğŸ†š non-V600E); classifications of #BRAF mutations. #precisionmedicine https://t.co/Ls3p52ijEs
312,Wed Apr 29 06:40:01 +0000 2020,Grainne Doyle,Important. We started doing it when pandemic came to Ireland.
313,Wed Apr 29 06:41:20 +0000 2020,Alex Dobrovic,Nice thread on the #ctDNA session at virtual #AACR20- thanks @pratt_ed #liquidbiopsy #earlydetection https://t.co/xDeTQGB7yH
314,Wed Apr 29 06:41:51 +0000 2020,Chris,"Next ""new drug on the horizon"" is an oral SERD (Selective Estrogen Receptor Degrader), GDC-9545. Achieved same efficacy as other SERDs, but at a lower dose.

Currently recruiting patients with #ER+ #MBC. 

#BCSM #AACR20 
https://t.co/7aWgt2Bv60"
315,Wed Apr 29 06:42:48 +0000 2020,IAEA PACT,Thread by @ADesaiMD: Missed #COVID19nCancer plenary in #AACR20 @AACR? Hereâ€™s a thread to catch up on all the fascinating global research presy: @AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@Oncoâ€¦ https://t.co/jiRO4nRWCM
316,Wed Apr 29 06:43:16 +0000 2020,ã¨ã‚ãã†ï¼ æ”¾å°„ç·šæ²»ç™‚åŒ»,"æ­¦æ¼¢ã‹ã‚‰ã®å¤šæ–½è¨­å¾Œã‚å‘ãç ”ç©¶ã€‚
â˜‘ï¸ãŒã‚“æ‚£è€…ã¯æ­»äº¡ã‚’å«ã‚ãŸé‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸è¡€æ¶²è…«ç˜ã¨è‚ºç™Œã€ç—…æœŸStageIVã®ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸æ²»ç™‚æ³•ã§ã¯ã€æ‰‹è¡“ã‚„å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³è–¬ã¯æœ‰æ„ã«é‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚æ”¾å°„ç·šæ²»ç™‚ã®æœ‰ç„¡ã§ã¯æœ‰æ„å·®ãªã—ã€‚"
317,Wed Apr 29 06:44:08 +0000 2020,RadiOncBOTjp,"æ­¦æ¼¢ã‹ã‚‰ã®å¤šæ–½è¨­å¾Œã‚å‘ãç ”ç©¶ã€‚
â˜‘ï¸ãŒã‚“æ‚£è€…ã¯æ­»äº¡ã‚’å«ã‚ãŸé‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸è¡€æ¶²è…«ç˜ã¨è‚ºç™Œã€ç—…æœŸStageIVã®ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸æ²»ç™‚æ³•ã§ã¯ã€æ‰‹è¡“ã‚„å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³è–¬ã¯æœ‰æ„ã«é‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚æ”¾å°„ç·šæ²»ç™‚ã®æœ‰ç„¡ã§ã¯æœ‰æ„å·®ãªã—ã€‚"
318,Wed Apr 29 06:51:09 +0000 2020,Evelyn,Important. We started doing it when pandemic came to Ireland.
319,Wed Apr 29 06:51:45 +0000 2020,Charles Swanton,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
320,Wed Apr 29 06:53:25 +0000 2020,Christian Orrenius,This was the structural disclosure many were waiting for at #AACR20 @AACR: Matthew LaMarche of @NovartisScience raising the curtain for clinical SHP2 inhibitor #TNO155. Structurally quite distinct from previous tool SHP099 in order to address phototox &amp; off-target liabilities https://t.co/iOeyie4nia
321,Wed Apr 29 06:57:36 +0000 2020,Pankaj Kumar Panda,Todayâ€™s @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20
322,Wed Apr 29 07:00:02 +0000 2020,Darlaine honey,"Good news, but Genentech, Inc. is only allowing women to be part of the trial. This is contrary FDA recommendations which suggests men be included in bc trials. #bcsm"
323,Wed Apr 29 07:03:48 +0000 2020,Diana King,Pre existing ESR1 mutations in early stage primary breast cancer predict failure of endocrine therapy and poor OS. This is important and should guide how we think about ER+ breast cancer. #aacr20 https://t.co/DC3ROEJt4l
324,Wed Apr 29 07:05:20 +0000 2020,Victoria Hendry,"Check recent content @NatureCancer
 about #ctDNA and #LiquidBiopsy in cancer:

- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!

https://t.co/OMPFaRGU65
https://t.co/SXvHYm5Hmw
https://t.co/e26wYMedBV
https://t.co/CErTHIOYvA

#AACR20 https://t.co/agOl6k5Zfh"
325,Wed Apr 29 07:05:34 +0000 2020,Jim Cavet is washing his hands at a safe distance,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
326,Wed Apr 29 07:07:01 +0000 2020,Phyllis Murphy wash yizzer hands,Important. We started doing it when pandemic came to Ireland.
327,Wed Apr 29 07:08:29 +0000 2020,Victoria Hendry,"Check recent content @NatureCancer about #ctDNA and #LiquidBiopsy in cancer:

- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!

https://t.co/BSc74nrBFa
https://t.co/0TgSQO7k9Y
https://t.co/KIxFN8Gu2k
https://t.co/HZlrrXXsN3

#AACR20"
328,Wed Apr 29 07:09:38 +0000 2020,Debbie Caswell,Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc
329,Wed Apr 29 07:10:28 +0000 2020,@Alejandro1926,Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combinationâ€™s activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu
330,Wed Apr 29 07:12:15 +0000 2020,#COVID19,#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF
331,Wed Apr 29 07:13:32 +0000 2020,AndrÃ© Luiz Morais Da Silva,"New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB"
332,Wed Apr 29 07:18:14 +0000 2020,rox,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
333,Wed Apr 29 07:21:21 +0000 2020,ONKOS,#AlligatorBioscience Presents Promising Interim Phase I Data for its #BispecificDrugCandidate #ATOR1015 at #AACR20 $ATORX https://t.co/HZuJw1DQGY
334,Wed Apr 29 07:23:37 +0000 2020,Professor Zoe Ellen Winters,"Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer https://t.co/m4Dr6kU662"
335,Wed Apr 29 07:25:15 +0000 2020,CubainformaciÃ³n.tv,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
336,Wed Apr 29 07:25:33 +0000 2020,Amy Gravell,"Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3"
337,Wed Apr 29 07:28:01 +0000 2020,SIRIC BRIO,"Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer"
338,Wed Apr 29 07:31:42 +0000 2020,TranslationalGenomic,Nice thread on the #ctDNA session at virtual #AACR20- thanks @pratt_ed #liquidbiopsy #earlydetection https://t.co/xDeTQGB7yH
339,Wed Apr 29 07:35:48 +0000 2020,TranslationalGenomic,"Great chairing from Dr Fertig @FertigLab &amp; Dr Turajlic @SamraTurajlic at ""Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease"" #AACR20 Virtual #science MinisympğŸ™Thanks @AACR for all efforts making this possible in challenging times! #StaySafe"
340,Wed Apr 29 07:36:12 +0000 2020,MASSIMO DESTRO,"Nuovi dati su #Vitrakvi e highlights sul nuovo AhR-inibitore presentati da @Bayer durante #AACR20.
La nostra #ricerca in #oncologia non si ferma. 
Trovare #nuovesoluzioni Ã© la nostra mission.
#scienceforabetterlife il nostro motto.
#StrongerTogether

https://t.co/vCE8rIqBa7"
341,Wed Apr 29 07:37:22 +0000 2020,"Ashley Love Sumrall, MD, FACP",I dream of a day when academicians will understand we donâ€™t know how to prevent lung cancer. We only know how to reduce risk in people who smoke. #lcsm #radonc
342,Wed Apr 29 07:37:55 +0000 2020,ONKOS,#AACR20: Iovance revels in promising lung cancer data out of Moffitt as TIL therapy triggers 2 complete responses https://t.co/cIi0bl2sLf
343,Wed Apr 29 07:39:11 +0000 2020,Khalid Alharbi ğŸ”¬,"Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
344,Wed Apr 29 07:39:18 +0000 2020,Future Oncology,"Check out our Editor's coffee chat, where we discuss our highlights from the first day of #AACR20! @NanomedZone @MyBioTechniques @OncologyCentral"
345,Wed Apr 29 07:41:36 +0000 2020,Pasquale Pisapia,"#OncoAlert #AACR20 Dr. Carlos Gomez-Martin presents #COVID19 data from Hospital 12 de Octubre in Madrid, Spain. Data slides not posted at his request but of note: higher proportion of patients with lung cancer, mortality 25%, radiographic changes common, neutropenia a major risk. https://t.co/s9JOTPgEur"
346,Wed Apr 29 07:41:51 +0000 2020,Oncology Central,That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y
347,Wed Apr 29 07:41:52 +0000 2020,Pasquale Pisapia,Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht
348,Wed Apr 29 07:41:59 +0000 2020,Pasquale Pisapia,#AACR20 thanks for sharing this slide. #immunotherapy usage #COVID19 #COVID19 @jsoriamd @GustaveRoussy @barlesi
349,Wed Apr 29 07:42:09 +0000 2020,Pasquale Pisapia,"#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2"
350,Wed Apr 29 07:42:22 +0000 2020,Pasquale Pisapia,#AACR20 more on PARPâ›”ï¸ #BRCA #DNA-Repair ğŸ§¬
351,Wed Apr 29 07:42:31 +0000 2020,Pasquale Pisapia,#Metabolism (Oncometabolites) and #DDR as targets to treat #cancer . #AACR20 #OncoAlert https://t.co/58jvSF5Skd
352,Wed Apr 29 07:43:31 +0000 2020,ONKOS,#AACR20: Early data suggest #Novartis' Incyte-discovered MET inhibitor helps lung cancer patients with brain lesions https://t.co/UR3ZCbxWX9
353,Wed Apr 29 07:43:44 +0000 2020,Unicancer,"#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse prÃ©coce de la maniÃ¨re dont ce #CLCC sâ€™est adaptÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie #COVID19
@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif"
354,Wed Apr 29 07:44:27 +0000 2020,ONKOS,"Capmatinib continues to show promise fr Met Exon 14 skipping NSCLC, including brain mets. Reinforces need for comprehensive biomarker testing to catch these rare mutations so our patients can benefit from these new drugs - LUNGevity SAB Dr. Eddie Garron @UCLAJCCC #AACR20 #LCSM https://t.co/s5GBmIMq3x"
355,Wed Apr 29 07:45:45 +0000 2020,thietkebietthukhonggianviet,The latest The Thiáº¿t káº¿ biá»‡t thá»± Ä‘áº¹p KhÃ´ng Gian Viá»‡t ! https://t.co/SmaQSV5Ic8 Thanks to @mndp023 @phoenixemk @Dr_ZiMingZhao #aacr20
356,Wed Apr 29 07:46:56 +0000 2020,ONKOS,"Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 cancer patients have a 15% mortality . Is this good outcome notably related to the almost 10% of patients who received compassionate #Tocilizumab ? 
https://t.co/dRmW2rAHaG https://t.co/1kc0iD9VcV"
357,Wed Apr 29 07:48:34 +0000 2020,EGFR Positive UK,"This slide was presented in the Lung Cancer Targeted Therapies session at #AACR20 today. As a healthy 47 year old when dx with stage IV #lungcancer completely out of the blue, with no known risk factors, I would like to know how I could have PREVENTED my LC #lcsm @AACRFoundation https://t.co/VIGVdFoHtB"
358,Wed Apr 29 07:49:46 +0000 2020,ONKOS,"What we learned at #AACR20 Day 1: 1. You CAN get 48,000+ participants to register for the worldâ€™s largest webinar (canâ€™t wait to see demographic data);
2. KRAS is Undrugged (*yet*), not Undruggable;
3. BRAF is the ultimate Hydra;           4. @AACR really came throughğŸ‘"
359,Wed Apr 29 07:50:19 +0000 2020,Maxime Meylan,"Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
360,Wed Apr 29 07:51:04 +0000 2020,ONKOS,#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr
361,Wed Apr 29 07:52:04 +0000 2020,Marcella,Important. We started doing it when pandemic came to Ireland.
362,Wed Apr 29 07:53:24 +0000 2020,ONKOS,#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF
363,Wed Apr 29 07:58:17 +0000 2020,ONKOS,"cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies."
364,Wed Apr 29 07:59:16 +0000 2020,ceann beag,Important. We started doing it when pandemic came to Ireland.
365,Wed Apr 29 07:59:32 +0000 2020,The Evidence BaseÂ®,"Check out our Editor's coffee chat, where we discuss our highlights from the first day of #AACR20! @NanomedZone @MyBioTechniques @OncologyCentral"
366,Wed Apr 29 07:59:32 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,These are great numbers @AACR - and so are the blockbuster number of residents. Great planning in short order to make #AACR20 virtual.
367,Wed Apr 29 08:00:01 +0000 2020,Bayer Pharma,Weâ€™re focused on genomic #cancer testing. These tests may help doctors recommend treatments and clinical trials based on a patientâ€™s unique tumor makeup. Learn about the importance of genomic cancer testing today: https://t.co/JJ2xbWEDR4 #AACR20 https://t.co/ZLuvR1cAE9
368,Wed Apr 29 08:06:20 +0000 2020,Lymphoma Hub,"ğŸ—£ï¸ What was your lymphoma highlight from Day 1 of #AACR20? Vote below, or let us know in the comments!  â¬‡ï¸#lymsm"
369,Wed Apr 29 08:06:55 +0000 2020,Dr. Cristiano Resende,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
370,Wed Apr 29 08:07:16 +0000 2020,AML Hub,Have your say ğŸ—£ï¸ What was your AML highlight from Day 1 at #AACR20? #leusm
371,Wed Apr 29 08:09:37 +0000 2020,Angrist Proteomics,"Metabolomic adaptations and correlates of survival to immune checkpoint blockade: https://t.co/bGMKiJQ75L

#AACR20 #biomarkers https://t.co/GFaoBgO9kx"
372,Wed Apr 29 08:10:22 +0000 2020,cacaskata,"Excited to have @BrendonStilesMD with us tmrw as we continue our discussions on management of #LungCancer during #COVID19, including updates from #AACR20 
@StephenVLiu @JackWestMD @n8pennell @OncLive @ginacolumbusonc #LCSM @OncoAlert"
373,Wed Apr 29 08:10:39 +0000 2020,BioTechniques,"Find out what the Editors of @OncologyCentral, @MyBioTechniques and @NanomedZone thought of day 1 #AACR20"
374,Wed Apr 29 08:10:57 +0000 2020,Guillermo Sanz,"Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
375,Wed Apr 29 08:14:19 +0000 2020,Oncology Advance,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
376,Wed Apr 29 08:14:22 +0000 2020,Oncology Advance,#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd
377,Wed Apr 29 08:18:24 +0000 2020,Deborah Armstrong,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
378,Wed Apr 29 08:28:06 +0000 2020,Guillermo Sanz,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
379,Wed Apr 29 08:32:20 +0000 2020,ZDQ&Interlaken,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
380,Wed Apr 29 08:33:56 +0000 2020,Stefania Colasanti,"Just outğŸ“£at @TheLancetOncol ğŸ“°by @OncoAlert ğŸš¨colleague @FAndreMD &amp;team. MonarcHER sees combo abemaciclib,fulvestrant, &amp;trastuzumab improved PFS Vs. SOC #chemotherapy +trastuzumab, w/a tolerable safetyâ€¼ï¸#breastcancer #aacr20 #bcsm https://t.co/ZLtdVsul0O https://t.co/gi8FMoJcrv"
381,Wed Apr 29 08:34:03 +0000 2020,Stefania Colasanti,"Thank you @AACR for a great first day of this Amazing #AACR20 , very very well done &amp; we are grateful for all your hard workâ€¼ï¸Here are some of the logistics from our friends at @symplur for today
Best,
@OncoAlert ğŸš¨
https://t.co/pGGYMfhVyP https://t.co/XZqjgjkCGv"
382,Wed Apr 29 08:34:10 +0000 2020,fabien reyal,#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd
383,Wed Apr 29 08:34:31 +0000 2020,Stefania Colasanti,"An amazing job with this Virtual #AACR20 , Kudosâ€¼ï¸  
Thank you very much to all the hard working people at @AACR for making this possibleâ€¼ï¸Way to set the barğŸ™Œ
Best from @weoncologists &amp; all of us at @OncoAlert ğŸš¨ https://t.co/R5MDUSCIQ9"
384,Wed Apr 29 08:34:42 +0000 2020,Stefania Colasanti,"Dear friends,
Quick Poll on which part of the worldğŸŒour Colleagues (Doctors, Nurses, Scientists &amp; Patient Advocates) attending #AACR20 are coming from, care to share?
best,
@weoncologists &amp; @OncoAlert ğŸš¨"
385,Wed Apr 29 08:34:45 +0000 2020,Stefania Colasanti,"Thank you @AACR , an Amazing Part 1âƒ£of  #AACR20 and thank you for making registration freeâ€¼ï¸Such details eliminates the economic issues many colleagues face in their countries &amp; makes it available to ALL, VERY well doneâ€¼ï¸"
386,Wed Apr 29 08:34:48 +0000 2020,Stefania Colasanti,Live #AACR20 Study from @MDAndersonNews Shows how Taking NaproxenğŸ’Šdaily may reduce the risk of developing #Colorectalcancer in people with #lynchSyndrome @OncoAlert ğŸš¨#CRC
387,Wed Apr 29 08:35:10 +0000 2020,Stefania Colasanti,"Our @OncoAlert ğŸš¨colleague @ErikaHamilton9 ğŸ‘©â€âš•ï¸of @SarahCannonDocs Live from #AACR20 discussing the I-SPY2 trial by @YaleCancer .Addition of durvalumab &amp; olaparib to neoadjuvant paclitaxel improved pCR in high-risk, HER2- stage II/III #breastcancer #BCSM
Edit: @weoncologists https://t.co/OWj0UnnxIh"
388,Wed Apr 29 08:35:14 +0000 2020,Stefania Colasanti,"Our @OncoAlert ğŸš¨colleague @itsnot_pink live from #AACR20 discussing EMBRACA trial led by @MDAndersonNews .Advanced #breastcancer patients w/ #BRCA mutation, talazoparib did not see improved OS compared to #chemotherapy 
However did see improved QOLâ€¼ï¸#BCSM
edited: @weoncologists https://t.co/9aMaP9tnXK"
389,Wed Apr 29 08:35:23 +0000 2020,Stefania Colasanti,"Coming up in ğŸ”Ÿminutes, part 2ï¸âƒ£of #AACR20 And @OncoAlert ğŸš¨will be there #OncoAlert ğŸŒ https://t.co/DTt6Jjr0I7"
390,Wed Apr 29 08:35:26 +0000 2020,Stefania Colasanti,Up next at #AACR20 our @OncoAlert ğŸš¨colleague @marinagarassino ğŸ‘©â€âš•ï¸to present #TERAVOLT A testament of how the #lungcancer come come@together and uniteâ€¼ï¸@peters_solange @barlesi @EnriquetaFelip @IASLC @HwakeleeMD
391,Wed Apr 29 08:35:37 +0000 2020,Stefania Colasanti,"Our @OncoAlert ğŸš¨colleague @BenWestphalen ğŸ§‘â€âš•ï¸from University of Munich on the #AACR20 GENIE project. Focus on Abstract 1092 on #BRAF mutations ğŸ§¬
Edited: @weoncologists https://t.co/sB0bII8C8G"
392,Wed Apr 29 08:35:41 +0000 2020,Stefania Colasanti,First results from #TERAVOLT are out and presented today at #AACR20 by our @myESMO @OncoAlert ğŸš¨colleague @marinagarassino ğŸ‘©â€âš•ï¸showing high mortality rate of #COVID19 in patients with thoracic malignancies.
393,Wed Apr 29 08:35:50 +0000 2020,Stefania Colasanti,"Our @OncoAlert ğŸš¨Colleague @LeciaSequist ğŸ‘©â€âš•ï¸of @MassGeneralNews Live from #AACR20 Discussing The Geometry Study and Zenith20. #LCSM @LungCancer 
Edited: @weoncologists https://t.co/U9ZPHynuZA"
394,Wed Apr 29 08:36:08 +0000 2020,Stefania Colasanti,"Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers
Edited: @weoncologists https://t.co/2rxks3qi8a"
395,Wed Apr 29 08:36:11 +0000 2020,Stefania Colasanti,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
396,Wed Apr 29 08:36:16 +0000 2020,Stefania Colasanti,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
397,Wed Apr 29 08:36:17 +0000 2020,Enric Barba IbÃ¡Ã±ez,Todayâ€™s @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20
398,Wed Apr 29 08:36:17 +0000 2020,Chiara CATANIA,"First up, Dr Zhang presents the experience of taking care of patients with COVID in Wuhan, China.  Lung cancer was the most common cancer seen in patients, but multiple other cancers were noted. #AACR20 https://t.co/LKBTvEtg5w"
399,Wed Apr 29 08:36:21 +0000 2020,Stefania Colasanti,"Our @OncoAlert ğŸš¨Colleague @CharuAggarwalMD ğŸ‘©â€âš•ï¸from @PennCancer  Virtually Live at #AACR20 discussing globalğŸŒpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino ğŸ‡®ğŸ‡¹&amp; The French experience by @barlesi from @GustaveRoussy ğŸ‡«ğŸ‡·
Edited: @weoncologists https://t.co/yJXXuVGIJV"
400,Wed Apr 29 08:36:29 +0000 2020,Stefania Colasanti,"Hereâ€™s what would help patients: 

If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. 

1/2

#AACR2020 @OncoAlert"
401,Wed Apr 29 08:36:33 +0000 2020,Stefania Colasanti,"As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert ğŸš¨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strongâ€¼ï¸ https://t.co/T8Cg4ptdzN"
402,Wed Apr 29 08:36:38 +0000 2020,Stefania Colasanti,"Dear Colleagues,
Thank you for a great couple of days of science, all of us at @OncoAlert ğŸš¨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2âƒ£.
Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC"
403,Wed Apr 29 08:36:47 +0000 2020,fabien reyal,"#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse prÃ©coce de la maniÃ¨re dont ce #CLCC sâ€™est adaptÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie #COVID19
@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif"
404,Wed Apr 29 08:36:38 +0000 2020,Stefania Colasanti,"Dear Colleagues,
Thank you for a great couple of days of science, all of us at @OncoAlert ğŸš¨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2âƒ£.
Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC"
405,Wed Apr 29 08:37:45 +0000 2020,Chiara CATANIA,"At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG"
406,Wed Apr 29 08:41:51 +0000 2020,PAO,Important. We started doing it when pandemic came to Ireland. https://t.co/pnODKXsAPW
407,Wed Apr 29 08:41:53 +0000 2020,Michael Duffy,Important. We started doing it when pandemic came to Ireland.
408,Wed Apr 29 08:46:18 +0000 2020,Oncology Forum UK,Can we predict which cancer patients will respond to #immunotherapy? Predictive biomarkers are currently being discussed at a minisymposium at the #AACR20 Virtual Annual Meeting. https://t.co/095y0qDmAn
409,Wed Apr 29 08:46:29 +0000 2020,Oncology Forum UK,Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM
410,Wed Apr 29 08:46:33 +0000 2020,Oncology Forum UK,"Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
411,Wed Apr 29 08:46:29 +0000 2020,Oncology Forum UK,Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM
412,Wed Apr 29 08:46:48 +0000 2020,Oncology Forum UK,"At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG"
413,Wed Apr 29 08:46:56 +0000 2020,Oncology Forum UK,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
414,Wed Apr 29 08:47:02 +0000 2020,Mehrpouya Mobin,"#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2"
415,Wed Apr 29 08:47:24 +0000 2020,Oncology Forum UK,"Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
416,Wed Apr 29 08:47:30 +0000 2020,Oncology Forum UK,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
417,Wed Apr 29 08:47:39 +0000 2020,Oncology Forum UK,"#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2"
418,Wed Apr 29 08:47:46 +0000 2020,Oncology Forum UK,"Facing previous data suggesting imunorresistance, this small exploratory analysis of KN042 exhibits IO monotherapy benefit for PDL1 &gt; 1% patients regardless of STK11/KEAP1 status. Nevertheless it seems insufficient to encourage mono IO as 1L for STK11/KEAP1 mut NSCLC. #AACR20 https://t.co/QviVJqAId1"
419,Wed Apr 29 08:48:27 +0000 2020,Oncology Forum UK,Todayâ€™s @US_FDA approval of an alternative dosing regimen for the immunotherapeutic pembrolizumab was based on results presented at the AACR Virtual Annual Meeting I: https://t.co/B2JeoSAC4N #AACR20
420,Wed Apr 29 08:48:30 +0000 2020,Oncology Forum UK,That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y
421,Wed Apr 29 08:48:41 +0000 2020,Oncology Forum UK,The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS
422,Wed Apr 29 08:49:05 +0000 2020,Oncology Forum UK,"Results were presented today during the Early Detection and ctDNA Clinical Plenary Session on the second day of #AACR20 Virtual Annual Meeting I.
https://t.co/4uEHUe1Hpn"
423,Wed Apr 29 08:49:14 +0000 2020,Oncology Forum UK,"#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU"
424,Wed Apr 29 08:49:21 +0000 2020,Oncology Forum UK,#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. David D. Thiel presents results from a study that tested a multicancer early detection liquid biopsy test designed to predict the presence or absence of cancer and the tissue of origin. https://t.co/v8y6FZvGOS
425,Wed Apr 29 08:49:28 +0000 2020,Oncology Forum UK,#AACR20 Virtual Annual Meeting I: Adoptive Cell Transfer Therapy Session. Ben Creelan presents results from a phase I trial. Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC). https://t.co/CzRhFEQL6I
426,Wed Apr 29 08:49:31 +0000 2020,Oncology Forum UK,"#AACR20 Virtual Annual Meeting I: Adoptive Cell Transfer Therapy Session. Xinxin Wang presents: Clinical safety and efficacy study of TruUCARâ„¢ GC027: The first-in-human, universal CAR T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). https://t.co/NMcFSXBDzG"
427,Wed Apr 29 08:49:34 +0000 2020,Oncology Forum UK,#AACR20 Virtual Annual Meeting I: Adoptive Cell Transfer Therapy Session. Haneen Shalabi presents findings on the safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL.
428,Wed Apr 29 08:49:37 +0000 2020,Oncology Forum UK,#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS
429,Wed Apr 29 08:50:56 +0000 2020,Oncology Forum UK,Kudos to @barlesi of @GustaveRoussy et al for this detailed analysis of cancer patients with #COVID19 @AACR #AACR20 @lalbiges @jsoria @FAndreMD https://t.co/jHBGoQr5a6
430,Wed Apr 29 08:51:06 +0000 2020,Oncology Forum UK,#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd
431,Wed Apr 29 08:52:23 +0000 2020,Angel Montero Luis,#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS
432,Wed Apr 29 08:52:50 +0000 2020,"Muhammad Husnain,MD","Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4"
433,Wed Apr 29 08:58:43 +0000 2020,Mehrpouya Mobin,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
434,Wed Apr 29 09:00:00 +0000 2020,Oncology Central,The latest results from the Circulating Cell-free Genome Atlas study have been presented at #AACR20. Find out more about the latest early detection test studies in our latest news post:
435,Wed Apr 29 09:01:37 +0000 2020,Christelle Basei,"ğŸ“¢ Pr Fabrice @barlesi @GustaveRoussy a prÃ©sentÃ© en plÃ©niÃ¨re #Covid19etCancer du congrÃ¨s #AACR20 une analyse prÃ©coce de la situation et la maniÃ¨re dont Gustave Roussy sâ€™est adaptÃ© avec agilitÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie de #covid19.

Lire le communiquÃ© : https://t.co/VPFdDJgHol"
436,Wed Apr 29 09:02:08 +0000 2020,Science and Innovation at Cancer Research UK,"We announced new #MRD surveillance data from the #TRACERx collaboration with @uclcancer, @TheCrick &amp; @CR_UK at #AACR20. Read the release: https://t.co/9W4ezkbVKv #AACR2020 https://t.co/M2T6pUSaDN"
437,Wed Apr 29 09:02:28 +0000 2020,Lluraldi Cabas Mayor,"Avances de #Vacuna cubana contra el cÃ¡ncer, fueron presentados en colaboraciÃ³n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituciÃ³n, existe un convenio de colaboraciÃ³n que estÃ¡ dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB"
438,Wed Apr 29 09:03:58 +0000 2020,Miguel Brno,The latest results from the Circulating Cell-free Genome Atlas study have been presented at #AACR20. Find out more about the latest early detection test studies in our latest news post:
439,Wed Apr 29 09:05:41 +0000 2020,Christelle Basei,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
440,Wed Apr 29 09:06:18 +0000 2020,Laura Dormer,"Check out our Editor's coffee chat, where we discuss our highlights from the first day of #AACR20! @NanomedZone @MyBioTechniques @OncologyCentral"
441,Wed Apr 29 09:07:19 +0000 2020,EIPG,The latest EIPG Pharma #ICYMI! https://t.co/ffTGNh75sh #pharma #pharmaceutical #aacr20
442,Wed Apr 29 09:07:27 +0000 2020,Christelle Basei,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
443,Wed Apr 29 09:09:33 +0000 2020,Valentina Gambardella,Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc
444,Wed Apr 29 09:10:05 +0000 2020,OncLive.com,"TERAVOLT Data Reveal ""Unexpectedly High"" Mortality in Patients With Thoracic Cancers and COVID-19 @IstTumori @AACR #COVID19 #coronavirus #AACR20 https://t.co/x8z3rAw5dS"
445,Wed Apr 29 09:10:57 +0000 2020,Enric Barba IbÃ¡Ã±ez,COVID-19: Practical and Immuno-Oncology Insight in Melanoma and Beyond @PAscierto @AACR #coronavirus #COVID19 #AACR20 https://t.co/XgQ8GsU8I6
446,Wed Apr 29 09:14:08 +0000 2020,Yixy Gavilan,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
447,Wed Apr 29 09:19:20 +0000 2020,Laia VilÃ ,TAK-788 ph2 in pts with EGFR exon 20 insertions treated at 160mg. ORR 43%. Responses seen in pretreated TKI/IO pts as well. Most common AE is GI tox. Food instructions has been updated in this study to improve GI tox. #AACR20 https://t.co/NJOR4A8xK5
448,Wed Apr 29 09:20:00 +0000 2020,Lymphoma Hub,âš¡ï¸ Highlights from the @AACR Annual Meeting 2020 in lymphoma are now available in this @lymphomahub Twitter Moment â–¶ï¸ https://t.co/1P9IBcn29K â—€ï¸ #lymsm #AACR20
449,Wed Apr 29 09:23:03 +0000 2020,Science and Innovation at Cancer Research UK,Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG
450,Wed Apr 29 09:24:18 +0000 2020,CancÃ©ropÃ´le GO,#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd
451,Wed Apr 29 09:24:27 +0000 2020,AML Hub,"âš¡ï¸ If you missed the @AACR meeting, click below to view a Twitter Moment created by the @AML_Hub, providing you with the latest updates in #AML from the meeting: https://t.co/KgiY9MSrYR #leusm #AACR20"
452,Wed Apr 29 09:27:25 +0000 2020,Rhizome333,"$VSTM CKI27 + defactinib in Kras mutant cancers, via Udai Banerji. Note responses in subjects on prior Mek inhibitor treatment #AACR20 https://t.co/agkGzF2ZWb"
453,Wed Apr 29 09:27:45 +0000 2020,Rhizome333,"$VSTM shows promise in Kras-mutated cancers at #AACR20, so why is it off 40%? Via @evaluatevantage https://t.co/oefEHadoNi"
454,Wed Apr 29 09:29:07 +0000 2020,Tobias Helmstorf,Weâ€™re focused on genomic #cancer testing. These tests may help doctors recommend treatments and clinical trials based on a patientâ€™s unique tumor makeup. Learn about the importance of genomic cancer testing today: https://t.co/JJ2xbWEDR4 #AACR20 https://t.co/ZLuvR1cAE9
455,Wed Apr 29 09:29:13 +0000 2020,"Pashtoon Kasi MD, MS","@Aiims1742 ğŸ‘‡ğŸ¼Interesting to note that while the discussion/data at #AACR20 showed a higher HR for #cancer &amp; #COVID19, (almost ~3), itâ€™s very likely that this potentially may be driven to some extent by other chronic conditions &amp; advanced age. #COVID19nCancer listed as â€˜malignant neoplasmâ€™. https://t.co/BPwVl3gQBM"
456,Wed Apr 29 09:30:14 +0000 2020,Angel Montero Luis,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
457,Wed Apr 29 09:32:00 +0000 2020,Dario Trapani,"@Aiims1742 ğŸ‘‡ğŸ¼Interesting to note that while the discussion/data at #AACR20 showed a higher HR for #cancer &amp; #COVID19, (almost ~3), itâ€™s very likely that this potentially may be driven to some extent by other chronic conditions &amp; advanced age. #COVID19nCancer listed as â€˜malignant neoplasmâ€™. https://t.co/BPwVl3gQBM"
458,Wed Apr 29 09:32:12 +0000 2020,Andrea Biondo,"Delighted to be part of the @ICR_DDU_IIT team running 3 phaseI trials, results of which have been presented at #AACR20"
459,Wed Apr 29 09:32:29 +0000 2020,Emily Smith,âš¡ï¸ Highlights from the @AACR Annual Meeting 2020 in lymphoma are now available in this @lymphomahub Twitter Moment â–¶ï¸ https://t.co/1P9IBcn29K â—€ï¸ #lymsm #AACR20
460,Wed Apr 29 09:32:43 +0000 2020,Emily Smith,"âš¡ï¸ If you missed the @AACR meeting, click below to view a Twitter Moment created by the @AML_Hub, providing you with the latest updates in #AML from the meeting: https://t.co/KgiY9MSrYR #leusm #AACR20"
461,Wed Apr 29 09:34:27 +0000 2020,Andrea Biondo,"Delighted to be part of the @ICR_DDU_IIT @royalmarsdenNHS running three phase 1 trials, results of which were presented at #AACR20"
462,Wed Apr 29 09:36:11 +0000 2020,gilberto lopes,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
463,Wed Apr 29 09:36:21 +0000 2020,gilberto lopes,"Check out this video by the amazing Dr. @CharuAggarwalMD. 

#OncoAlert 
#AACR20"
464,Wed Apr 29 09:37:15 +0000 2020,gilberto lopes,"Thanks #AACR20 - It has been fantastic, I'm amazed of how such gigantic conference has adapted so quickly to the difficulties! I'm grateful for the new interactions and for the outlook of the field, the cancer research community stands strong! See you again in June! ğŸ˜"
465,Wed Apr 29 09:44:19 +0000 2020,Angie Bee,Important. We started doing it when pandemic came to Ireland.
466,Wed Apr 29 09:44:20 +0000 2020,Lars Wortmann,Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM
467,Wed Apr 29 02:18:48 +0000 2020,kyaw zin thein,"Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
468,Wed Apr 29 02:20:49 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"A significant difference between shedders &amp; non shedders in screening, lead time &amp; DFS. Could pre op status of patient ctDNA be a potential biomarker? Stresses tissue biopsy critical if the ctDNA is negative #AACR20 #LCSM"
469,Wed Apr 29 09:45:44 +0000 2020,giuseppe viscardi,"Thanks #AACR20 - It has been fantastic, I'm amazed of how such gigantic conference has adapted so quickly to the difficulties! I'm grateful for the new interactions and for the outlook of the field, the cancer research community stands strong! See you again in June! ğŸ˜"
470,Wed Apr 29 09:46:37 +0000 2020,giuseppe viscardi,"Thanks #AACR2020
See you in June for Virtual Annual Meeting II"
471,Wed Apr 29 09:54:42 +0000 2020,Tasuku Ishida,å‡„ã¾ã˜ã„çµæœã ãªã€ã“ã‚Œ
472,Wed Apr 29 09:54:48 +0000 2020,OncoAlert,"#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse prÃ©coce de la maniÃ¨re dont ce #CLCC sâ€™est adaptÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie #COVID19
@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif"
473,Wed Apr 29 09:55:49 +0000 2020,Debbie Caswell,Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg
474,Wed Apr 29 09:59:22 +0000 2020,Abhijit Pal,"Delighted to be part of the @ICR_DDU_IIT @royalmarsdenNHS running three phase 1 trials, results of which were presented at #AACR20 https://t.co/0AbGAz99OF"
475,Wed Apr 29 09:59:33 +0000 2020,European Immuno-Oncology,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
476,Wed Apr 29 10:00:36 +0000 2020,Symplur Hashtags,Top Influencers of #AACR20: @AACR @OncoAlert @weoncologists @Jbauml @marinagarassino @barlesi @tmprowell More ğŸ“Š https://t.co/RpQ7HRwmN3
477,Wed Apr 29 10:03:02 +0000 2020,Kerry A Kauffman,Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG
478,Wed Apr 29 10:04:47 +0000 2020,Kerry A Kauffman,Top Influencers of #AACR20: @AACR @OncoAlert @weoncologists @Jbauml @marinagarassino @barlesi @tmprowell More ğŸ“Š https://t.co/RpQ7HRwmN3
479,Wed Apr 29 10:08:42 +0000 2020,Pablo Alonso,"â€œThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,â€ says @DavidHongMD. 

Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer"
480,Wed Apr 29 10:08:55 +0000 2020,ThunderContainer,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
481,Wed Apr 29 10:10:07 +0000 2020,OncLive.com,"WATCH: Nickolas Papadopoulos, PhD, of @HopkinsMedicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer. @AACR #AACR20 https://t.co/tEgRPfjPSC"
482,Wed Apr 29 10:13:54 +0000 2020,@crukgreenock,"Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team
https://t.co/6tRnpjoAIl"
483,Wed Apr 29 10:15:20 +0000 2020,Robin Davison,"@ScienceMagazine @CellPressNews @MountSinaiNYC Potential therapies to treat #COVID19 hyperinflammation. #CytokineStorm

Targets: GM-CSF, IL-17, IL-23, TNF, IL-6, JAK &amp; IL-1

Companies: $IMAB $HGEN $GSK $RHHBY $SNY $REGN $EUSA $NVS $INCY $AMGN $PFE $LLY $ABBV $BMY $ALPMY $ALXN $KNSA $SOBI $JNJ @Roivant

https://t.co/bLGxRlKKu1"
484,Wed Apr 29 10:21:57 +0000 2020,Kerry A Kauffman,Read the Clinical Trials collection - newly released for the #AACR20 Virtual Annual Meeting I! https://t.co/TCMvqxZcxC https://t.co/UEmZK1wAGW
485,Wed Apr 29 10:22:29 +0000 2020,"Wafik S. El-Deiry, MD, PhD, FACP",The latest The Cancer News Daily! https://t.co/OfWNStOvgo Thanks to @PennCancer @FDAOncology #ascoconnection #aacr20
486,Wed Apr 29 10:22:55 +0000 2020,Brad Loncar,STAT story on this Gracell allo data. Definitely one of the more intriguing things we saw at #AACR20. https://t.co/EQJ9wzHiJk
487,Wed Apr 29 10:24:37 +0000 2020,Arael SÃ¡nchez SardiÃ±,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
488,Wed Apr 29 10:25:23 +0000 2020,Annarita Egidi,"For the first time, weâ€™re disclosing the molecular structure of mobocertinib (TAK-788)! Join us tomorrow during #AACR20â€™s virtual annual meeting at 11:14AM EST to learn more."
489,Wed Apr 29 10:32:59 +0000 2020,Joe Gambiste,"$VSTM shows promise in Kras-mutated cancers at #AACR20, so why is it off 40%? Via @evaluatevantage https://t.co/oefEHadoNi"
490,Wed Apr 29 10:34:28 +0000 2020,pasmo,"cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies."
491,Wed Apr 29 10:35:06 +0000 2020,Matthias Scheffler,"Thank you @AACR , an Amazing Part 1âƒ£of  #AACR20 and thank you for making registration freeâ€¼ï¸Such details eliminates the economic issues many colleagues face in their countries &amp; makes it available to ALL, VERY well doneâ€¼ï¸"
492,Wed Apr 29 10:41:39 +0000 2020,@gulleyj1,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
493,Wed Apr 29 10:42:36 +0000 2020,Jorge Darcourt,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience
494,Wed Apr 29 10:45:18 +0000 2020,ã‚†ããã‚‚ã›ã‚“ã›ãƒ¼@æ”¾å°„ç·šæ²»ç™‚åŒ»,"æ­¦æ¼¢ã‹ã‚‰ã®å¤šæ–½è¨­å¾Œã‚å‘ãç ”ç©¶ã€‚
â˜‘ï¸ãŒã‚“æ‚£è€…ã¯æ­»äº¡ã‚’å«ã‚ãŸé‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸è¡€æ¶²è…«ç˜ã¨è‚ºç™Œã€ç—…æœŸStageIVã®ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸æ²»ç™‚æ³•ã§ã¯ã€æ‰‹è¡“ã‚„å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³è–¬ã¯æœ‰æ„ã«é‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚æ”¾å°„ç·šæ²»ç™‚ã®æœ‰ç„¡ã§ã¯æœ‰æ„å·®ãªã—ã€‚"
495,Wed Apr 29 10:46:49 +0000 2020,Chantal,"Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
496,Wed Apr 29 10:48:31 +0000 2020,Alessandro Carrer,"""~19% of cancer patients harbor RAS mutations"" per recent study in #CancerResearch @AACR journal. Not so much the 30% quoted historically. Wide variability across cancers.... #AACR20 https://t.co/ylUH2mMMQW https://t.co/nr0TfPFGR9"
497,Wed Apr 29 10:51:07 +0000 2020,Manav Pathania ğŸ³ï¸â€ğŸŒˆ,"New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB"
498,Wed Apr 29 10:52:41 +0000 2020,"Pashtoon Kasi MD, MS","This is hugeğŸ‘‡ğŸ¼

#Immunotherapy dosing esp amidstğŸ’¡ on how to â¬‡ï¸exposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 

@US_FDA @FDAOncology Approves @Merck #KEYTRUDAâ–#pembrolizumab

â¡ï¸400 mg Q6ï¸âƒ£Weeksâœ…

#OncoAlert 
https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu"
499,Wed Apr 29 10:53:13 +0000 2020,Jose Luis Camellon,"Avances de #Vacuna cubana contra el cÃ¡ncer, fueron presentados en colaboraciÃ³n con @RoswellPark en #EEUU. Entre el @centro_cim y dicha instituciÃ³n, existe un convenio de colaboraciÃ³n que estÃ¡ dando evidencias y resultados. #CienciaCubana @BioCubaFarma @DrRobertoMOjeda @DiazCanelB"
500,Wed Apr 29 10:53:36 +0000 2020,PINK AND BLUE MOVIE,"Good news, but Genentech, Inc. is only allowing women to be part of the trial. This is contrary FDA recommendations which suggests men be included in bc trials. #bcsm"
501,Wed Apr 29 10:55:35 +0000 2020,Ramcelo GarcÃ­a Morales,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
502,Wed Apr 29 10:56:49 +0000 2020,MD Anderson Leukemia,"â€œThese data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,â€ says @DavidHongMD. 

Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer"
503,Wed Apr 29 10:57:16 +0000 2020,D. Russler-Germain,"This is hugeğŸ‘‡ğŸ¼

#Immunotherapy dosing esp amidstğŸ’¡ on how to â¬‡ï¸exposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 

@US_FDA @FDAOncology Approves @Merck #KEYTRUDAâ–#pembrolizumab

â¡ï¸400 mg Q6ï¸âƒ£Weeksâœ…

#OncoAlert 
https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu"
504,Wed Apr 29 10:57:18 +0000 2020,#StayHome,"This is hugeğŸ‘‡ğŸ¼

#Immunotherapy dosing esp amidstğŸ’¡ on how to â¬‡ï¸exposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 

@US_FDA @FDAOncology Approves @Merck #KEYTRUDAâ–#pembrolizumab

â¡ï¸400 mg Q6ï¸âƒ£Weeksâœ…

#OncoAlert 
https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu"
505,Wed Apr 29 10:57:51 +0000 2020,Personalized Med Jnl,The latest results from the Circulating Cell-free Genome Atlas study have been presented at #AACR20. Find out more about the latest early detection test studies in our latest news post:
506,Wed Apr 29 10:57:55 +0000 2020,kkm,"You can never be too respectful, so always err on the side of showing more, not less, respect. #pallonc #oncology #hapc #nursing"
507,Wed Apr 29 10:58:48 +0000 2020,"Charu Aggarwal, MD, MPH","#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert 
@PennMedicine @PennMedNews"
508,Wed Apr 29 10:59:58 +0000 2020,"Pashtoon Kasi MD, MS",ğŸ†•âœ…#CRCSM #LCSM #BCSM #Cancer #HPBCSM #StomachCancer #EsophagealCancer #ColorectalCancer #LungCancer #LynchSyndrome #PANCSM #ANCSM #ESOCSM #HNCSM #LYMSM #MELSM #PEDCSM  and agnostic dMMR/MSI-High indicationğŸ‘‡ğŸ¼
509,Wed Apr 29 11:00:32 +0000 2020,ARM,"Off-the-shelf CAR-T therapy helps leukemia patients in a small, first-in-human trial https://t.co/LCblW4C8JG via @sxbegle  #AACR20"
510,Wed Apr 29 11:04:34 +0000 2020,OncoAlert,"#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert 
@PennMedicine @PennMedNews"
511,Wed Apr 29 11:04:49 +0000 2020,OncoAlert,"This is hugeğŸ‘‡ğŸ¼

#Immunotherapy dosing esp amidstğŸ’¡ on how to â¬‡ï¸exposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 

@US_FDA @FDAOncology Approves @Merck #KEYTRUDAâ–#pembrolizumab

â¡ï¸400 mg Q6ï¸âƒ£Weeksâœ…

#OncoAlert 
https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu"
512,Wed Apr 29 11:06:26 +0000 2020,milandreu,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
513,Wed Apr 29 11:07:06 +0000 2020,brigada chacon,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
514,Wed Apr 29 11:07:56 +0000 2020,Onfire,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
515,Wed Apr 29 11:08:00 +0000 2020,BIOCOM Africa,"Join #abcam for virtual #AACR20 next week, when Abcamâ€™s scientific experts will discuss how to advance cancer research as well as current industry trends and challenges. New talks and Q&amp;A sessions daily, April 27- May 1. Program here: https://t.co/cA2rGPqpaV https://t.co/hki2X183Ng"
516,Wed Apr 29 11:09:13 +0000 2020,Aglaya DÃ­az,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
517,Wed Apr 29 11:10:08 +0000 2020,OncLive.com,"cfDNA Assay Shows Predictive Value in Detecting Cancer, Tissue of Origin @MayoClinic @AACR #AACR20 https://t.co/qWgCNPMA6E"
518,Wed Apr 29 11:10:11 +0000 2020,Quitterie Lanta,"#CanceretCOVID19 : Pr Fabrice @barlesi de @GustaveRoussy partage une analyse prÃ©coce de la maniÃ¨re dont ce #CLCC sâ€™est adaptÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie #COVID19
@AACR  #AACR2020 #OncoAlert #TousEnsemble #cancer #CLCC #Villejuif"
519,Wed Apr 29 11:10:12 +0000 2020,Edison A. Carrasco,"Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 cancer patients have a 15% mortality . Is this good outcome notably related to the almost 10% of patients who received compassionate #Tocilizumab ? 
https://t.co/dRmW2rAHaG https://t.co/1kc0iD9VcV"
520,Wed Apr 29 11:10:18 +0000 2020,Brendon Stiles,"#COVID19 #AACR20 #LCSM
TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.
198 pts evaluated with 34.6% of death rate.
Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi"
521,Wed Apr 29 11:10:33 +0000 2020,Edison A. Carrasco,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
522,Wed Apr 29 11:11:04 +0000 2020,CDNCC MICONS,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
523,Wed Apr 29 11:11:16 +0000 2020,"Charu Aggarwal, MD, MPH","#AACR20 Part I was a success. Huge congratulations to the entire @AACR team for this incredible #virtual effort! We look forward to part II in June, w/a special session on #COVID19 in #Cancer. But before that, looking forward to #ASCO20 @ASCO"
524,Wed Apr 29 11:11:45 +0000 2020,Colleen Lance,"Oncologists are very used to see the Kaplan-Meier curve. For COVID-19, the curve shows statistically significant with Y-axis represented by days, not even months. It is a very sad outcome. Thanks, @AACR for providing this opportunity to learn so that we can fight w/data. #AACR20 https://t.co/VtVTqPxd3b"
525,Wed Apr 29 11:11:55 +0000 2020,Edison A. Carrasco,Kudos to @barlesi of @GustaveRoussy et al for this detailed analysis of cancer patients with #COVID19 @AACR #AACR20 @lalbiges @jsoria @FAndreMD https://t.co/jHBGoQr5a6
526,Wed Apr 29 11:12:01 +0000 2020,Abcam,"Do you have a few minutes? Interested in ICC? Join our #VirtualEvent today for ""Introduction to #Immunocytochemistry: principles, protocol steps &amp; troubleshootingâ€ with Antonella Galli. Join us daily as we stream our #AACR20 content, April 27- May 1. https://t.co/zW0EMb3fF3 https://t.co/a74UO0EFYv"
527,Wed Apr 29 11:13:57 +0000 2020,Edison A. Carrasco,"Hereâ€™s what would help patients: 

If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. 

1/2

#AACR2020 @OncoAlert"
528,Wed Apr 29 11:15:04 +0000 2020,"`((,(Dieter 'Hovekamp)))",#NOXXON Presents Latest Clinical Data From the Phase 1/2 #NOXA12 / #KeytrudaÂ® Combination Trial in #ColorectalCancer and #PancreaticCancer at the #AACR20 $ALNOX https://t.co/JMOXuY8FpI
529,Wed Apr 29 11:15:57 +0000 2020,"Nathan A. Pennell MD, PhD, FASCO",#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0
530,Wed Apr 29 11:16:07 +0000 2020,Dr Joseph McCollom DO,"This is hugeğŸ‘‡ğŸ¼

#Immunotherapy dosing esp amidstğŸ’¡ on how to â¬‡ï¸exposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 

@US_FDA @FDAOncology Approves @Merck #KEYTRUDAâ–#pembrolizumab

â¡ï¸400 mg Q6ï¸âƒ£Weeksâœ…

#OncoAlert 
https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu"
531,Wed Apr 29 11:16:09 +0000 2020,Biotech-Catalyst,"@ScienceMagazine @CellPressNews @MountSinaiNYC Potential therapies to treat #COVID19 hyperinflammation. #CytokineStorm

Targets: GM-CSF, IL-17, IL-23, TNF, IL-6, JAK &amp; IL-1

Companies: $IMAB $HGEN $GSK $RHHBY $SNY $REGN $EUSA $NVS $INCY $AMGN $PFE $LLY $ABBV $BMY $ALPMY $ALXN $KNSA $SOBI $JNJ @Roivant

https://t.co/bLGxRlKKu1"
532,Wed Apr 29 11:17:10 +0000 2020,"Nathan A. Pennell MD, PhD, FASCO","We should immediately move to switch stable patients to q6 week pembro, will be a big help in reducing unnecessary visits! #COVIDãƒ¼19 #LCSM"
533,Wed Apr 29 11:17:30 +0000 2020,"`((,(Dieter 'Hovekamp)))",STAT story on this Gracell allo data. Definitely one of the more intriguing things we saw at #AACR20. https://t.co/EQJ9wzHiJk
534,Wed Apr 29 11:17:40 +0000 2020,1stOncology,#IntelliaTherapeutics to Present New Preclinical Data fromÂ ItsÂ #CRISPR/#Cas9 ProgramsÂ at the 23rd AnnualÂ Meeting of the #AACR20 $NTLA https://t.co/jWIl5t7x3I
535,Wed Apr 29 11:18:25 +0000 2020,jose chaple,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
536,Wed Apr 29 11:19:47 +0000 2020,"Darcy Burbage, DNP, RN, AOCN","#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert 
@PennMedicine @PennMedNews"
537,Wed Apr 29 11:22:10 +0000 2020,Julio F. de CossÃ­o,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
538,Wed Apr 29 11:23:01 +0000 2020,Andrew Hong,That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y
539,Wed Apr 29 11:24:12 +0000 2020,MSKHemOncTrials,"Today's #AACR20's plenary session is #COVID19 and #Cancer. Tune in to hear from MSK's Dr. Louis Voigt, as he presents ""#COVID19 and cancer: Flattening the curve but widening disparities."" @AACR  https://t.co/JGQPnbAwHH"
540,Wed Apr 29 11:25:09 +0000 2020,Brendon Stiles,"Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:
â¬†ï¸ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op
#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1"
541,Wed Apr 29 11:25:28 +0000 2020,"Jason Luke, MD, FACP","Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9"
542,Wed Apr 29 11:25:32 +0000 2020,MSKHemOncTrials,"Today at 3:50pm tune in to #AACR20's minisymposium ""Evaluating #Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease,"" to hear from @KellyLBolton on ""Oncologic therapy shapes the fitness landscape of #ClonalHematopoiesis."" https://t.co/OGd2f4qvSM https://t.co/PF7CXsVcvq"
543,Wed Apr 29 11:25:45 +0000 2020,MSKHemOncTrials,It's day 2 of #AACR20. For more info on the virtual meeting &amp; what MSK experts will be featured please visit our website. @AACR https://t.co/qBHR2hbBy3
544,Wed Apr 29 11:26:49 +0000 2020,MSKHemOncTrials,"CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R"
545,Wed Apr 29 11:28:29 +0000 2020,Biotech-Catalyst,"CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb"
546,Wed Apr 29 11:28:48 +0000 2020,"Randy C. Miles, MD, MPH","Improved duration of good quality of life, but no improvement in overall survival #bcsm #metastaticbreastcancer https://t.co/m4Dr6kU662"
547,Wed Apr 29 11:29:01 +0000 2020,D. Russler-Germain,"CONGRESS | #AACR20 | Jonathan Pachter discusses the synergistic action of the dual PI3K inhibitor, duvelisib, with PD-1 blockage in solid tumor and lymphoma models. A clinical trial of duvelisib + nivolumab in tFL and Richterâ€™s transformation is ongoing #lymsm https://t.co/aJwPboXCDS"
548,Wed Apr 29 11:29:24 +0000 2020,ã˜ã‚“,New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer
549,Wed Apr 29 11:29:28 +0000 2020,ã˜ã‚“,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚"
550,Wed Apr 29 11:29:41 +0000 2020,abderrahim raissi,"#AACR20 Reminder that #WordsMatter. Just heard ""Many of our pts are metastatic."" Pts don't metastasize. Tumors do. Pts are not their disease so: ""Many of our pts have metastatic dz."" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP"
551,Wed Apr 29 11:30:03 +0000 2020,D. Russler-Germain,"CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R"
552,Wed Apr 29 11:30:06 +0000 2020,Eugenia Riveiro,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
553,Wed Apr 29 11:32:34 +0000 2020,Medicine Matters oncology,#AACR20 news: Camrelizumabâ€“apatinib has antitumor activity in previously treated #SCLC patients - #PASSION trial data reported by Jie Wang at #AACR2020 #lungcancer #lcsm https://t.co/hVur2GIwAz
554,Wed Apr 29 11:33:13 +0000 2020,ã˜ã‚“,é‡è¦ï¼
555,Wed Apr 29 11:33:56 +0000 2020,medwireNews,#AACR20 news: Camrelizumabâ€“apatinib has antitumor activity in previously treated #SCLC patients - #PASSION trial data reported by Jie Wang at #AACR2020 #lungcancer #lcsm https://t.co/hVur2GIwAz
556,Wed Apr 29 11:34:52 +0000 2020,Christian Aguila,#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF
557,Wed Apr 29 11:35:04 +0000 2020,Roberto LÃ³pez HernÃ¡ndez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
558,Wed Apr 29 11:36:37 +0000 2020,Lynda Williams,#AACR20 news: Camrelizumabâ€“apatinib has antitumor activity in previously treated #SCLC patients - #PASSION trial data reported by Jie Wang at #AACR2020 #lungcancer #lcsm https://t.co/hVur2GIwAz
559,Wed Apr 29 11:37:07 +0000 2020,ã˜ã‚“,"æ­¦æ¼¢ã‹ã‚‰ã®å¤šæ–½è¨­å¾Œã‚å‘ãç ”ç©¶ã€‚
â˜‘ï¸ãŒã‚“æ‚£è€…ã¯æ­»äº¡ã‚’å«ã‚ãŸé‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸è¡€æ¶²è…«ç˜ã¨è‚ºç™Œã€ç—…æœŸStageIVã®ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸æ²»ç™‚æ³•ã§ã¯ã€æ‰‹è¡“ã‚„å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³è–¬ã¯æœ‰æ„ã«é‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚æ”¾å°„ç·šæ²»ç™‚ã®æœ‰ç„¡ã§ã¯æœ‰æ„å·®ãªã—ã€‚"
560,Wed Apr 29 11:38:06 +0000 2020,é¦¬ä¸»æ¥ğŸã‚³ãƒ“ãƒƒãƒˆãƒ•ã‚¡ã‚¤ã‚¿ãƒ¼æ´¾ æ‰‹ã‚’æ´—ã†æ”¾å°„ç·šæ²»ç™‚åŒ»,"æ­¦æ¼¢ã‹ã‚‰ã®å¤šæ–½è¨­å¾Œã‚å‘ãç ”ç©¶ã€‚
â˜‘ï¸ãŒã‚“æ‚£è€…ã¯æ­»äº¡ã‚’å«ã‚ãŸé‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸è¡€æ¶²è…«ç˜ã¨è‚ºç™Œã€ç—…æœŸStageIVã®ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚
â˜‘ï¸æ²»ç™‚æ³•ã§ã¯ã€æ‰‹è¡“ã‚„å…ç–«ãƒã‚§ãƒƒã‚¯ãƒã‚¤ãƒ³ãƒˆé˜»å®³è–¬ã¯æœ‰æ„ã«é‡ç—‡åŒ–ãƒªã‚¹ã‚¯ãŒé«˜ã„ã€‚æ”¾å°„ç·šæ²»ç™‚ã®æœ‰ç„¡ã§ã¯æœ‰æ„å·®ãªã—ã€‚ https://t.co/ltEwNXcliw"
561,Wed Apr 29 11:38:13 +0000 2020,é¦¬ä¸»æ¥ğŸã‚³ãƒ“ãƒƒãƒˆãƒ•ã‚¡ã‚¤ã‚¿ãƒ¼æ´¾ æ‰‹ã‚’æ´—ã†æ”¾å°„ç·šæ²»ç™‚åŒ»,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚ https://t.co/OFppgUN3XK"
562,Wed Apr 29 11:38:32 +0000 2020,é¦¬ä¸»æ¥ğŸã‚³ãƒ“ãƒƒãƒˆãƒ•ã‚¡ã‚¤ã‚¿ãƒ¼æ´¾ æ‰‹ã‚’æ´—ã†æ”¾å°„ç·šæ²»ç™‚åŒ»,New data from AACR.  Note that patients w/#cancer who received #radiation did not show statistically significant differences in having any severe events when compared with patients without cancer https://t.co/41pUGEvmeG
563,Wed Apr 29 11:38:47 +0000 2020,é¦¬ä¸»æ¥ğŸã‚³ãƒ“ãƒƒãƒˆãƒ•ã‚¡ã‚¤ã‚¿ãƒ¼æ´¾ æ‰‹ã‚’æ´—ã†æ”¾å°„ç·šæ²»ç™‚åŒ»,#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS
564,Wed Apr 29 11:38:58 +0000 2020,Ryo. Oncology,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
565,Wed Apr 29 11:40:39 +0000 2020,Mathieu Rousseau,"@n8pennell Lung cancer pts seem to do worse as a subgroup. 

@AACR #AACR20 

Pts with lung cancer, hematologic cancer, or with metastatic cancer (stage IV) had the highest frequency of severe events.

https://t.co/cgqZIOWSUl"
566,Wed Apr 29 11:42:22 +0000 2020,Rakel RodrÃ­guez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
567,Wed Apr 29 11:42:34 +0000 2020,ESAZUCAR,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
568,Wed Apr 29 11:43:27 +0000 2020,Filip Janku,"People with #LynchSyndrome are more likely to develop #colorectalcancer. But, a study led by our @evilarsan shows taking naproxen daily may reduce that risk: https://t.co/5RNLdY3TGk #AACR20 #endcancer"
569,Wed Apr 29 11:44:02 +0000 2020,Bursatil Biotech,Great timing after #AACR20
570,Wed Apr 29 11:44:46 +0000 2020,ãƒ©ã‚¸ã‚¨ãƒ¼ã‚·ãƒ§ãƒ³çŒ«(ãƒ©ã‚¸ã­ã“),"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚"
571,Wed Apr 29 11:45:19 +0000 2020,Debra Gottsleben,Great jo @GustaveRoussy team! https://t.co/i6raJVTpWt
572,Wed Apr 29 11:47:12 +0000 2020,Javier Montes,El futuro del diagnÃ³stico del cÃ¡ncer. MÃ¡s inversiÃ³n en investigaciÃ³n en sistemas de cribado y en diagnÃ³stico en fases tempranas salvarÃ­a mÃ¡s vidas que cualquier nuevo tratamiento
573,Wed Apr 29 11:47:21 +0000 2020,Normy_cnap,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
574,Wed Apr 29 11:48:08 +0000 2020,Pedro Monzon Barata,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
575,Wed Apr 29 11:49:23 +0000 2020,janet murray,New phase 2 trial results show that addition of Imprime PGG to pembrolizumab is a promising treatment for patients with #metastatic triple-negative #breastcancer #AACR20 https://t.co/6MZSEknwLh
576,Wed Apr 29 11:51:05 +0000 2020,Cortellis,"Positive preclinical and FIH data presented for IPN-60090, a potent GLS1 inhibitor for the oral treatment of KEAP1/NFE2L2-mutant NSCLC and ASNS-low HGSOC under joint development by MD Anderson Center and Ipsen. #AACR20"
577,Wed Apr 29 11:51:07 +0000 2020,"Tom John, MBBS, PhD","#COVID19 #AACR20 #LCSM
TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.
198 pts evaluated with 34.6% of death rate.
Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi"
578,Wed Apr 29 11:51:33 +0000 2020,JLFrÃ­asA,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
579,Wed Apr 29 11:53:55 +0000 2020,fernando rojas g,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
580,Wed Apr 29 11:57:21 +0000 2020,Nickels Steamroller,A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24
581,Wed Apr 29 11:58:28 +0000 2020,Ana Iris Victoria,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
582,Wed Apr 29 11:59:02 +0000 2020,"Pashtoon Kasi MD, MS",#AACR20 #COVID19 https://t.co/NLnCsxOEvt
583,Wed Apr 29 12:00:34 +0000 2020,ãµã‹ã‚“ã˜ã‚…(ä¸è¦³æ¨¹ éœ²ç”Ÿ)@å²¡å±±,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚ https://t.co/OFppgUN3XK"
584,Wed Apr 29 12:01:10 +0000 2020,Targeted Oncology,"Interim findings of the ongoing phase II ZENITH20 trial demonstrated that poziotinib induced a 68.7% disease control rate when used as treatment of patients with pretreated nonâ€“small cell lung cancer harboring an EGFR exon 20 insertion.
https://t.co/DnJFvZUxr0 #AACR20"
585,Wed Apr 29 12:01:17 +0000 2020,Cortellis,"Syndax Pharmaceuticals presents preliminary phase I data for SNDX-5613, their lead menin/MLL interaction inhibitor for the oral treatment of MLL-rearranged (MLL-r) and NPM1-mutant acute leukemias; responses observed in two patients with MLL-r acute leukemia. #AACR20"
586,Wed Apr 29 12:02:10 +0000 2020,Kevin Brent Cook,"There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J"
587,Wed Apr 29 12:03:22 +0000 2020,umi,"ã€Œæ³¨ç›®ã™ã¹ãã¯ã€æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ãŸãŒã‚“æ‚£è€…ã¯ã€éæ‹…ãŒã‚“æ‚£è€…ã«æ¯”è¼ƒã—ã¦ã€(è¨³æ³¨:COVID-19ã«é–¢ã—ã¦)é‡ç—‡ã«ãªã‚‹ã‹ã©ã†ã‹ã«ã€çµ±è¨ˆå­¦çš„æœ‰æ„å·®ã¯ç„¡ã‹ã£ãŸã€

ASTRO(ç±³å›½æ”¾å°„ç·šè…«ç˜å­¦ä¼š)ãŒ #AACR20 (2020å¹´ã®ã‚ªãƒ³ãƒ©ã‚¤ãƒ³é–‹å‚¬ã•ã‚ŒãŸç±³å›½ãŒã‚“å­¦ä¼š)ã§ç™ºè¡¨ã•ã‚ŒãŸæ­¦æ¼¢ã®å¤§å­¦ç—…é™¢ã‹ã‚‰ã®ãƒ‡ãƒ¼ã‚¿ã‚’å¼•ç”¨ã—ã¦ã„ã¾ã™ã€‚ https://t.co/OFppgUN3XK"
588,Wed Apr 29 12:04:20 +0000 2020,Dr ESHA J,Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO
589,Wed Apr 29 12:05:16 +0000 2020,Dr ESHA J,A good reminder at #AACR20 from Dr. Sharma about the differences between fundamental immune targets in cancer - different opportunities for benefit from different mechanisms https://t.co/gu7BbOPi24
590,Wed Apr 29 12:05:20 +0000 2020,NCI Center for Cancer Research,Haneen Shalabi @NCI_CCR_PedOnc presented her team's findings at yesterday's virtual #AACR20
591,Wed Apr 29 12:06:10 +0000 2020,AML Hub,The @AML_Hub disseminates the latest evidence-based information on acute myeloid #leukemia. Proud to be recognized again as a top #leusm influencer during #AACR20! â¬‡ï¸ https://t.co/XVLb5wpEAu
592,Wed Apr 29 12:06:55 +0000 2020,Reinerio Feria Sanchez,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
593,Wed Apr 29 12:07:53 +0000 2020,Dr ESHA J,Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM
594,Wed Apr 29 12:08:04 +0000 2020,NCI Center for Cancer Research,Haneen Shalabi @NCI_CCR_PedOnc presented her team's findings at yesterday's virtual #AACR20. Read more https://t.co/MBdU2T0r7n via @onclive
595,Wed Apr 29 12:08:46 +0000 2020,Dr ESHA J,Great presentation by Dr. Padmanee Sharma of @MDAndersonNews @AACR #AACR20 on why PD-1 and PD-L1 inhibitors performed poorly in #mCRPC to date and what the next steps should be https://t.co/0vT59YkLKy
596,Wed Apr 29 12:09:36 +0000 2020,Dr ESHA J,"#AACR20 starts as a virtual meeting with 54,000 ppl

An important meeting held in this format:
Should others follow?

ğŸ‘‰No facility/flight expenses
ğŸ‘‰Reduced environment impact
ğŸ‘‰Reduce $ to register
ğŸ‘‰More can participate globally
ğŸ‘‰More important information disseminated https://t.co/OPSjKPNWsG"
597,Wed Apr 29 12:09:59 +0000 2020,Dr ESHA J,That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y
598,Wed Apr 29 12:10:07 +0000 2020,Dr ESHA J,"Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9"
599,Wed Apr 29 12:10:08 +0000 2020,OncLive.com,WATCH: Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer @YaleCancer @AACR #bcsm #AACR20 https://t.co/8aJEhb74Lf
600,Wed Apr 29 12:10:10 +0000 2020,Dr ESHA J,IMspire150 just presented at #AACR20 in metastatic #melanoma. Important PFS data up to 12m which may help individualize selection of initial therapies for BRAFmut pts. Longer FU to access who are the long responders (PD1 driven only? or synergistic effect?) is needed. https://t.co/I5gJ5C0BVr
601,Wed Apr 29 12:10:13 +0000 2020,Dr ESHA J,"Unbelievably unacceptable presentation going on by @cityofhope.  Lung cancer is preventable? Tell that to @VirginiaMByrne (dead- no risk factors). Or tell it to me (neversmoker) #aacr20, you can do better. #lcsm https://t.co/13lloILxmU"
602,Wed Apr 29 12:10:18 +0000 2020,Dr ESHA J,"Baller co-fellow, physician-scientist, and desk neighbor @JZimmermanMDPhD presents her work at #AACR20 virtually:
''miR-21 inhibition in mice models of pancreatic cancer''

She talks organoids, I talk OCM, @jaffeejaffee/ @laherda mentor both. Incredible to be at @hopkinskimmel! https://t.co/om7WtTTHj2"
603,Wed Apr 29 12:10:18 +0000 2020,Armando Ruiz DÃ­az,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
604,Wed Apr 29 12:10:35 +0000 2020,Dr ESHA J,"STK11 and KEAP1 mutations in KEYNOTE-042. STK11 mutation a/w lower PD-L1 expression. Pembro a/w better outcomes compared with chemo, regardless of STK11 or KEAP1 mutation status. Very low ORR with chemo in STK11 mutation+ NSCLC.
#AACR20 @OncoAlert https://t.co/Nqe7NetuCO"
605,Wed Apr 29 12:10:38 +0000 2020,henri brun,Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb
606,Wed Apr 29 12:10:41 +0000 2020,Dr ESHA J,"Facing previous data suggesting imunorresistance, this small exploratory analysis of KN042 exhibits IO monotherapy benefit for PDL1 &gt; 1% patients regardless of STK11/KEAP1 status. Nevertheless it seems insufficient to encourage mono IO as 1L for STK11/KEAP1 mut NSCLC. #AACR20 https://t.co/QviVJqAId1"
607,Wed Apr 29 12:10:45 +0000 2020,Dr ESHA J,"What we learned at #AACR20 Day 1: 1. You CAN get 48,000+ participants to register for the worldâ€™s largest webinar (canâ€™t wait to see demographic data);
2. KRAS is Undrugged (*yet*), not Undruggable;
3. BRAF is the ultimate Hydra;           4. @AACR really came throughğŸ‘"
608,Wed Apr 29 12:10:52 +0000 2020,Dr ESHA J,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
609,Wed Apr 29 12:10:55 +0000 2020,Dr ESHA J,WATCH: Dr. Pusztai on Rationale for the I-SPY 2 Trial With Durvalumab/Olaparib Combo in HER2- Breast Cancer @YaleCancer @AACR #bcsm #AACR20 https://t.co/8aJEhb74Lf
610,Wed Apr 29 12:11:04 +0000 2020,Dr ESHA J,Good news for #EGFR #exon20 patients! FDA granted Breakthrough Therapy Designation for @TakedaOncology  mobocertinib (TAK-788) for patients w/ #EGFR #exon20 after platinum-based chemotherapy. Will be discussed tomorrow at #AACR20 #LCSM @EGFRResisters @Exon20Group
611,Wed Apr 29 12:11:10 +0000 2020,Dr ESHA J,"I am not sure what to make of the multiple presentations at #AACR20 that ask for slides to not be posted.  I am looking out for it and not posting images of the slides, but its a bit odd in the setting of a meeting that is completely online with free universal access."
612,Wed Apr 29 12:11:14 +0000 2020,Andres Cervantes,Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc
613,Wed Apr 29 12:11:17 +0000 2020,Dr ESHA J,"#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU"
614,Wed Apr 29 12:11:20 +0000 2020,Dr ESHA J,"#AACR20 Reminder that #WordsMatter. Just heard ""Many of our pts are metastatic."" Pts don't metastasize. Tumors do. Pts are not their disease so: ""Many of our pts have metastatic dz."" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP"
615,Wed Apr 29 12:11:38 +0000 2020,Dr ESHA J,#AACR20 Virtual Annual Meeting Program Chair Antoni Ribas opens the special Clinical Plenary Session on COVID-19 and Cancer. https://t.co/2c42aOUazm
616,Wed Apr 29 12:11:49 +0000 2020,Dr ESHA J,Conclusion for TERAVOLT registry presentation on #AACR20 https://t.co/hR3R47wVNK
617,Wed Apr 29 12:11:51 +0000 2020,a beltran,Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark
618,Wed Apr 29 12:11:53 +0000 2020,Dr ESHA J,"#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh"
619,Wed Apr 29 12:11:59 +0000 2020,Dr ESHA J,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
620,Wed Apr 29 12:12:03 +0000 2020,Dr ESHA J,"Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz"
621,Wed Apr 29 12:12:18 +0000 2020,Dr ESHA J,"STOP patient shaming! If you must say â€œpreventionâ€, consider using the more accurate phrase of â€œrisk reduction.â€

As a vegetarian for 20 yrs, avid half marathoner, no history of #breastcancer, &amp; diagnosed #metastatic at 34- my cancer was not preventable.

#BCSM #LCSM #AACR20"
622,Wed Apr 29 12:12:22 +0000 2020,Dr ESHA J,TAK-788 ph2 in pts with EGFR exon 20 insertions treated at 160mg. ORR 43%. Responses seen in pretreated TKI/IO pts as well. Most common AE is GI tox. Food instructions has been updated in this study to improve GI tox. #AACR20 https://t.co/NJOR4A8xK5
623,Wed Apr 29 12:12:25 +0000 2020,Dr ESHA J,Being presented NOW at #AACR20 Virtual Annual Meeting Plenary Session on #COVID19 and Cancer!
624,Wed Apr 29 12:12:28 +0000 2020,Dr ESHA J,Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc
625,Wed Apr 29 12:12:38 +0000 2020,Dr ESHA J,As an #IM resident I am pleased to watch #AACR20 live stream virtual meeting while preparing my shift fighting #COVID19 ğŸ¥Š Thank to all who is making this happen @AACR @Rick__Buck @AACRPres &amp; who increased awareness @cancerassassin1 @Aiims1742 @DrSGraff @tmprowell  @OncoAlert ğŸ‘ğŸ» https://t.co/Dj9U74w9Tm
626,Wed Apr 29 12:12:50 +0000 2020,Dr ESHA J,Kudos to @barlesi of @GustaveRoussy et al for this detailed analysis of cancer patients with #COVID19 @AACR #AACR20 @lalbiges @jsoria @FAndreMD https://t.co/jHBGoQr5a6
627,Wed Apr 29 12:12:55 +0000 2020,Dr ESHA J,"Thank you so much to the #AACR20 organizers for making this possible: kudos for organizing a seamless event even in the face of #COVID19 . Very thoughtful discussion, tons of participation from the audience and some very cool #cancer tweep connections. See y'all tomorrow! https://t.co/tUxR4msXCN"
628,Wed Apr 29 12:12:59 +0000 2020,Dr ESHA J,"Regarding response assessment, ctDNA exhibit more eminent clinical application. Exploratory analysis from FLAURA correlate ctDNA clearance w/ â¬†ï¸PFS. Could a individualized approach w/ early ctDNA reassessment guide the decision of escalating or de-escalating treatment? #AACR20 https://t.co/qgv3RC5eq1"
629,Wed Apr 29 12:13:17 +0000 2020,Dr ESHA J,"It's weird not hearing standard applause from the audience as we would have otherwise in person at #AACR20. Maybe after each Virtual Presentation, we should post GIFs instead."
630,Wed Apr 29 12:13:20 +0000 2020,Dr ESHA J,"KRAS/RAS co-occurrence and mutual exclusivity by tumor types. STK11, ATM, KEAP1 have high co-occurrence patterns with KRAS mutated NSCLC #AACR20 https://t.co/2II78VFUwc"
631,Wed Apr 29 12:13:24 +0000 2020,Dr ESHA J,"This is a critical slide - capmatinib has clear efficacy in the brain.  We knew it got in, but the fact that we are seeing IC responses is very important.  As I mentioned above, this draws an important distinction from crizotinib where CNS efficacy is rare. #AACR20 #LCSM https://t.co/QFd0uHSgU3"
632,Wed Apr 29 12:13:47 +0000 2020,AliveAndKickn,Live #AACR20 Study from @MDAndersonNews Shows how Taking NaproxenğŸ’Šdaily may reduce the risk of developing #Colorectalcancer in people with #lynchSyndrome @OncoAlert ğŸš¨#CRC
633,Wed Apr 29 12:13:49 +0000 2020,Dr ESHA J,"#OncoAlert #AACR20 Dr. Carlos Gomez-Martin presents #COVID19 data from Hospital 12 de Octubre in Madrid, Spain. Data slides not posted at his request but of note: higher proportion of patients with lung cancer, mortality 25%, radiographic changes common, neutropenia a major risk. https://t.co/s9JOTPgEur"
634,Wed Apr 29 12:13:51 +0000 2020,Dr ESHA J,"Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:
â¬†ï¸ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op
#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1"
635,Wed Apr 29 12:13:53 +0000 2020,Maria Virginia Bluthgen,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
636,Wed Apr 29 12:13:54 +0000 2020,Dr ESHA J,"At #AACR20, Dr Jimeno presents data on mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding OX40L, made for tumor injection, given alone or with the PD-L1 inhibitor durvalumab. https://t.co/JPXn4wjlrT"
637,Wed Apr 29 12:13:57 +0000 2020,Dr ESHA J,Phase I study of COM701 (PVRIG targeting Ab) monoTx (Arm A) or in combo with nivolumab (Arm B). N=28. No DLTs in both arms. PR seen in primary peritoneal cancer (n=1) and MSS-CRC (n=1). Interesting target deserving further evaluation. #AACR20 https://t.co/zqPjjEVsQF
638,Wed Apr 29 12:14:00 +0000 2020,Dr ESHA J,Clinical activity of TAK-788 - 160 mg qd recommended dose for Phase II #AACR20 https://t.co/BbjUFD1vJD
639,Wed Apr 29 12:14:04 +0000 2020,Dr ESHA J,"Ha! I spy with my little eye... that I am on the list of #AACR20 influencers! ğŸ¤©ğŸ¤“ Just did a profile pic change right in time , so look out for my former me"
640,Wed Apr 29 12:13:53 +0000 2020,Maria Virginia Bluthgen,Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ
641,Wed Apr 29 12:14:05 +0000 2020,Dr ESHA J,"First up, Dr Zhang presents the experience of taking care of patients with COVID in Wuhan, China.  Lung cancer was the most common cancer seen in patients, but multiple other cancers were noted. #AACR20 https://t.co/LKBTvEtg5w"
642,Wed Apr 29 12:14:09 +0000 2020,Dr ESHA J,Bispecifics @ #AACR20 | Bispecific abstract (5672) for ABBV-428 mesothelin (MSLN) x CD40 BiAb https://t.co/2gdFvO2akk
643,Wed Apr 29 12:14:11 +0000 2020,Internal Medicine at Iowa,"This is hugeğŸ‘‡ğŸ¼

#Immunotherapy dosing esp amidstğŸ’¡ on how to â¬‡ï¸exposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 

@US_FDA @FDAOncology Approves @Merck #KEYTRUDAâ–#pembrolizumab

â¡ï¸400 mg Q6ï¸âƒ£Weeksâœ…

#OncoAlert 
https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu"
644,Wed Apr 29 12:14:13 +0000 2020,Dr ESHA J,Early cancer detection &amp; ctDNA session: still hold more questions than answers. Specificity was the presentersâ€™ focus but concerns regarding sensibility (including positive patients demanding rule-out tests) &amp; optimal test schedule to magnify cost-effectiveness yet exist. #AACR20
645,Wed Apr 29 12:14:51 +0000 2020,Ariel Fernan Rodrig,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
646,Wed Apr 29 12:15:00 +0000 2020,Shu Yazaki,#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU
647,Wed Apr 29 12:15:45 +0000 2020,Lymphoma Hub,The @lymphomahub aims to lift levels of knowledge in #lymphoma and CLL. We are proud to be recognized as a top #lymsm influencer during #AACR20!â¬‡ï¸ https://t.co/pDRKMo3Gz0
648,Wed Apr 29 12:16:47 +0000 2020,Gustavo Alberto de Cardenas Otero,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
649,Wed Apr 29 12:18:56 +0000 2020,Elaine Schattner,"Experimental blood test helped detect women's cancers early, study finds. But it missed many more cancers than it found, raised false alarms, &amp; only looked at ages 65-75, @MMarchioneAP - https://t.co/K1DGMdcE5J @DrLen #womenshealth #AACR20 @ScienceMagazine https://t.co/jkeSxv5I9S"
650,Wed Apr 29 12:19:11 +0000 2020,hidey_takeï¼ˆæ­¦å³¶å—£è‹±ï¼‰,æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ã¦ã‚‚Covid-19æ„ŸæŸ“ã«å¯¾ã™ã‚‹å…ç–«æ©Ÿèƒ½ã¯è½ã¡ãªã„ã‚ˆã†ã§ã™ï¼ˆè‚ºãŒã‚“ã«ã¤ã„ã¦ã¯æœªçŸ¥ï¼‰ã€‚
651,Wed Apr 29 12:21:00 +0000 2020,Vladmir Claudio Cordeiro de Lima,Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20
652,Wed Apr 29 12:21:26 +0000 2020,Manuel Bazan Milian ,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
653,Wed Apr 29 12:22:44 +0000 2020,hidey_takeï¼ˆæ­¦å³¶å—£è‹±ï¼‰,æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ã¦ã‚‚Covid-19ã«å¯¾ã™ã‚‹å…ç–«æ©Ÿèƒ½ã¯è½ã¡ãªã„ã¿ãŸã„ï¼ˆè‚ºãŒã‚“ã«ã¤ã„ã¦ã¯æœªçŸ¥ï¼‰ã€‚
654,Wed Apr 29 12:24:13 +0000 2020,Alexandra Winter,One more time for the folks in the backâ€” #WordsMatter
655,Wed Apr 29 12:24:20 +0000 2020,I-Mei Siu,"Look forward to seeing the entire study in print, but fortunately we got a glimpse at #AACR20: https://t.co/iUIuu99rEo"
656,Wed Apr 29 12:27:25 +0000 2020,M-LujÃ¡n OncologÃ­a,#AACR20 Virtual Annual Meeting Program Chair Antoni Ribas opens the special Clinical Plenary Session on COVID-19 and Cancer. https://t.co/2c42aOUazm
657,Wed Apr 29 12:28:25 +0000 2020,Catherine Janese,Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combinationâ€™s activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu
658,Wed Apr 29 12:30:10 +0000 2020,Yutaka Kurebayashi,"Tumor mutation burden (TMB) high and low in human tumors, AACR2020"
659,Wed Apr 29 12:32:08 +0000 2020,OncoAlert,"Our @OncoAlert ğŸš¨Colleague @CharuAggarwalMD ğŸ‘©â€âš•ï¸from @PennCancer  Virtually Live at #AACR20 discussing globalğŸŒpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino ğŸ‡®ğŸ‡¹&amp; The French experience by @barlesi from @GustaveRoussy ğŸ‡«ğŸ‡·
Edited: @weoncologists https://t.co/yJXXuVGIJV"
660,Wed Apr 29 12:32:11 +0000 2020,#StayHome,"Our @OncoAlert ğŸš¨Colleague @CharuAggarwalMD ğŸ‘©â€âš•ï¸from @PennCancer  Virtually Live at #AACR20 discussing globalğŸŒpresentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino ğŸ‡®ğŸ‡¹&amp; The French experience by @barlesi from @GustaveRoussy ğŸ‡«ğŸ‡·
Edited: @weoncologists https://t.co/yJXXuVGIJV"
661,Wed Apr 29 12:32:37 +0000 2020,Tanya Bondar,"âš¡ï¸Check the recent publication @NatureCancer by @corsellos @toddgolub1 on discovering the anticancer potential of non-oncology drugs - it's a must read!

https://t.co/ZGW16wtDhd
https://t.co/ARXAr4WWq7 

#AACR20 https://t.co/Jm3a9zrgWD https://t.co/y87gdeLIet"
662,Wed Apr 29 12:33:09 +0000 2020,Aakash Desai,"This is hugeğŸ‘‡ğŸ¼

#Immunotherapy dosing esp amidstğŸ’¡ on how to â¬‡ï¸exposure of #cancer patients amidst  #COVID19 #coronavirus #pandemic. #COVID19nCancer #AACR20 

@US_FDA @FDAOncology Approves @Merck #KEYTRUDAâ–#pembrolizumab

â¡ï¸400 mg Q6ï¸âƒ£Weeksâœ…

#OncoAlert 
https://t.co/g6HfMWGshU https://t.co/s1oJjN0Ycu"
663,Wed Apr 29 12:34:19 +0000 2020,Katsuaki Maehara Ph.D. ğŸ‡¯ğŸ‡µ,"#COVID19 and #Cancer: watch my quick summary on the data presented at #AACR20 by @marinagarassino #TERAVOLT and @barlesi talking about the @GustaveRoussy experience. #LCSM @OncoAlert 
@PennMedicine @PennMedNews"
664,Wed Apr 29 12:34:24 +0000 2020,RadiOncBOTjp,æ”¾å°„ç·šæ²»ç™‚ã‚’å—ã‘ã¦ã‚‚Covid-19ã«å¯¾ã™ã‚‹å…ç–«æ©Ÿèƒ½ã¯è½ã¡ãªã„ã¿ãŸã„ï¼ˆè‚ºãŒã‚“ã«ã¤ã„ã¦ã¯æœªçŸ¥ï¼‰ã€‚
665,Wed Apr 29 12:34:48 +0000 2020,"Nathan A. Pennell MD, PhD, FASCO","#COVID19 #AACR20 #LCSM
TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.
198 pts evaluated with 34.6% of death rate.
Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi"
666,Wed Apr 29 12:35:22 +0000 2020,palma(@miguelangelpalma),"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
667,Wed Apr 29 12:35:26 +0000 2020,@lisaksheldon,@OncologyNursing #clinicaltrials Can ship oral #cancer agents - injectable agents must be administered at a registered @FDA site @theNCI #AACR2020
668,Wed Apr 29 12:13:42 +0000 2020,Dr ESHA J,"#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2"
669,Wed Apr 29 12:36:36 +0000 2020,Percy Mauricio Fuentes Ortiz,"Why arenâ€™t all medicines taken as pills? Teresa Klinowska, Global Project Leader in Oncology, explains some of the decisions that go into how medicines are developed. #SciencefromAtoZ #AACR20 https://t.co/yuoe3QQtf1"
670,Wed Apr 29 12:37:01 +0000 2020,JCellBiol,ICYMI â€“ Special Collection of Reviews on #Cancer Cell Biology #AACR20: https://t.co/6J6PUDn4r4 https://t.co/LZzZy11mu5
671,Wed Apr 29 12:37:41 +0000 2020,Angel Casamayor,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd"
672,Wed Apr 29 12:37:48 +0000 2020,Toya,"CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R"
673,Wed Apr 29 12:38:26 +0000 2020,@lisaksheldon,Includes #cancer #survivorship research @OncologyNursing @theNCI
674,Wed Apr 29 12:39:36 +0000 2020,Gil Morgan,"Thanks @weoncologists 
Cc: @MGHThoracicOnc @EGFRResisters @Exon20Group"
675,Wed Apr 29 12:40:45 +0000 2020,ACS Research,"Link to our recent paper. Great work by Liam Spurr @lfspurr, Giuseppe Lamberti @GLambertiMD with wonderful leadership by Andy Cherniack and Mark Awad. https://t.co/WIg6vm0JX4"
676,Wed Apr 29 12:40:50 +0000 2020,"Marta Salido, PhD",New prospective data on outcomes with IO for NSCLC based on STK11 and KEAP1 status. Certainly limitations with only subset with available NGS results. Some of my best IO responders have been 2 STK11-mut patients. Not ready to skip IO for these patients yet. #AACR20 #LCSM https://t.co/1T8Mwt9hTu
677,Wed Apr 29 12:41:48 +0000 2020,Rogelio Montero,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
678,Wed Apr 29 12:45:44 +0000 2020,The Hope Foundation for Cancer Research,"Thanks for the coverage of our @SWOG trial results presented at #AACR20, @jasoncology and @OncLive!
https://t.co/av8vGk7toM via @onclive"
679,Wed Apr 29 12:47:57 +0000 2020,CiudadanoLibre,"Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigaciÃ³n, desarrollo y producciÃ³n de medicamentos, presenta prometedores resultados de ensayo clÃ­nico en congreso sobre oncologÃ­a. Otra demostraciÃ³n del prestigio de nuestra industria farmaceutica. #SomosCuba"
680,Wed Apr 29 12:48:20 +0000 2020,Indhiramg,"Just OutğŸ“£at @NEJM ğŸ“°In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genesğŸ§¬w/a role in homologous recombination repair, olaparib was associated w/longer PFSâ€¼ï¸ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN"
681,Wed Apr 29 12:48:23 +0000 2020,Syed Mohi Ahmed,"@Jbauml @StephenVLiu . In looking at #COVID19 in #lcsm @ #AACR20, was any data presented on egfr/alk/ros mutation? Is it truly lung cancer that was the risk factor or was lung cancer a surrogate for pre-existing lung disease?"
682,Wed Apr 29 12:48:46 +0000 2020,Marie Broderick,Important. We started doing it when pandemic came to Ireland.
683,Wed Apr 29 12:48:54 +0000 2020,AbbVie France,"ğŸ“¢ Pr Fabrice @barlesi @GustaveRoussy a prÃ©sentÃ© en plÃ©niÃ¨re #Covid19etCancer du congrÃ¨s #AACR20 une analyse prÃ©coce de la situation et la maniÃ¨re dont Gustave Roussy sâ€™est adaptÃ© avec agilitÃ© pour gÃ©rer lâ€™Ã©pidÃ©mie de #covid19.

Lire le communiquÃ© : https://t.co/VPFdDJgHol"
684,Wed Apr 29 12:50:51 +0000 2020,Inf y cancer UdeA,#AACR20 Virtual Annual Meeting Program Chair Antoni Ribas opens the special Clinical Plenary Session on COVID-19 and Cancer. https://t.co/2c42aOUazm
685,Wed Apr 29 12:51:34 +0000 2020,Arjun Gupta,#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0
686,Wed Apr 29 12:56:36 +0000 2020,mtmdphd,"@n8pennell 1) n=107 likely not large enough for multivariate analysis, 2) XRT &amp; Pneumonitis - see: 
Pneumonitis incidence in NSCLC Tx'd w/ immunotherapy or chemo in clinical trials &amp; real-world data [Apr 27, 2020 ] Liu et al. #AACR20 CT086 - VCTPL08 - https://t.co/VkpILtNFbu #lcsm #irAE"
